[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 236
1. Maeda H, Shibuya H, Suzuki K, Kuwabara M, Tsukise A, Sato T: A case of anaplastic meningioma in a dog. J Vet Med Sci; 2005 Nov;67(11):1177-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of anaplastic meningioma in a dog.
  • This tumor was diagnosed as anaplastic meningioma, which is rarely observed in dogs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327232.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Vimentin
  •  go-up   go-down


2. Comtesse N, Zippel A, Walle S, Monz D, Backes C, Fischer U, Mayer J, Ludwig N, Hildebrandt A, Keller A, Steudel WI, Lenhof HP, Meese E: Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets. Proc Natl Acad Sci U S A; 2005 Jul 5;102(27):9601-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are numerous studies on the immune response against malignant human tumors.
  • We assembled a panel of 62 meningioma-expressed antigens that show reactivity with serum antibodies of meningioma patients, including 41 previously uncharacterized antigens by screening of a fetal brain expression library.
  • We tested the panel for reactivity with 48 sera, including sera of patients with common-type, atypical, and anaplastic meningioma, respectively.
  • Meningioma sera detected an average of 14.6 antigens per serum and normal sera an average of 7.8 antigens per serum (P = 0.0001).
  • We found a decline of seroreactivity with malignancy with a statistical significant difference between common-type and anaplastic meningioma (P < 0.05).
  • More than 80% of meningioma patients had antibodies against at least one of the antigens KIAA1344, SC65, SOX2, and C6orf153.
  • The frequent antibody response against specific antigens offers new diagnostic and therapeutic targets for meningioma.
  • We developed a statistical learning method to differentiate sera of meningioma patients from sera of healthy donors.
  • [MeSH-major] Antibodies, Neoplasm / blood. Antibody Formation / immunology. Antigens, Neoplasm / immunology. Meningioma / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3560-8 [10589772.001]
  • [Cites] J Exp Med. 1999 Sep 20;190(6):815-26 [10499920.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Biochem Biophys Res Commun. 2001 May 11;283(3):634-40 [11341771.001]
  • [Cites] Cytogenet Cell Genet. 2001;93(3-4):207-20 [11528114.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 18;290(2):830-8 [11785977.001]
  • [Cites] Oncogene. 2002 Jan 10;21(2):239-47 [11803467.001]
  • [Cites] Semin Cancer Biol. 2002 Feb;12(1):25-31 [11926408.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):999-1005 [12407407.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):73-84 [12532422.001]
  • [Cites] Cancer Immun. 2001 Mar 30;1:4 [12747765.001]
  • [Cites] J Immunol. 2003 Dec 1;171(11):5956-63 [14634107.001]
  • [Cites] Int J Oncol. 2004 Feb;24(2):257-63 [14719100.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1420-7 [14691456.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):51-60 [15305375.001]
  • [Cites] Hum Genet. 1987 Dec;77(4):349-51 [2891603.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5863-7 [2393856.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):542-6 [8421688.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Sep 15;195(2):686-96 [8373407.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):827-32 [7717450.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4696-701 [7553651.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3 [8524854.001]
  • [Cites] Mol Biol Cell. 1996 Jul;7(7):1015-24 [8862517.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] J Biol Chem. 1997 Jul 18;272(29):17907-11 [9218414.001]
  • [Cites] Hum Mol Genet. 1997 Nov;6(12):2031-41 [9356211.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Hum Mol Genet. 1998 Nov;7(12):1859-72 [9811929.001]
  • [Cites] Nucleic Acids Res. 1999 Mar 15;27(6):1409-20 [10037800.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2158-66 [10090922.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4198-203 [10760287.001]
  • (PMID = 15983380.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / DNA Primers
  • [Other-IDs] NLM/ PMC1172238
  •  go-up   go-down


3. Munshi A, Dutta D, Muzumdar D, Jalali R: An atypical presentation of recurrent temporal lobe meningioma with external auditory canal mass. Indian J Cancer; 2007 Jul-Sep;44(3):119-21
MedlinePlus Health Information. consumer health - Hearing Disorders and Deafness.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An atypical presentation of recurrent temporal lobe meningioma with external auditory canal mass.
  • Extracranial spread of recurrent meningiomas involving the middle ear is rare.
  • MRI revealed a lesion in the right temporal lobe suggestive of meningioma.
  • She was re-operated and histopathology was anaplastic meningioma.
  • [MeSH-major] Deafness / etiology. Ear Canal / pathology. Ear Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / surgery. Temporal Lobe / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18250535.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


Advertisement
4. Lee GC, Choi SW, Kim SH, Kwon HJ: Multiple extracranial metastases of atypical meningiomas. J Korean Neurosurg Soc; 2009 Feb;45(2):107-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple extracranial metastases of atypical meningiomas.
  • Meningiomas are usually benign neoplasms in which extracranial metastases occur very rarely.
  • We report a case of multiple extracranial metastases of an atypical meningioma following a local recurrence.
  • We performed a total mass removal, and the histopathologic findings were consistent with benign meningioma.
  • Eight months later, the meningioma recurred.
  • The histopathologic findings showed atypical meningioma.
  • The histopathologic findings of the spinal tumors showed atypical meningioma.
  • The results from perirenal biopsies were consistent with metastatic meningioma.
  • In conclusion, extracranial metastasis as well as local recurrence must be considered in atypical or anaplastic meningioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 2008;204(5):305-14 [18374497.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Mar 15;25(6):727-31 [10752106.001]
  • [Cites] J Neurosurg. 1964 Dec;21:1098-102 [14281384.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Neuropathol Appl Neurobiol. 1997 Dec;23(6):496-506 [9460716.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Oncology (Williston Park). 1996 May;10(5):747-56; discussion 756-9 [8738830.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(10):1172-7; discussion 1177-8 [8955436.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):478-82 [2915253.001]
  • [Cites] J Neurosurg. 1985 May;62(5):763-6 [3989597.001]
  • [Cites] AJNR Am J Neuroradiol. 1982 May-Jun;3(3):267-76 [6805276.001]
  • [Cites] Br J Cancer. 1978 Apr;37(4):644-7 [646935.001]
  • [Cites] Cancer. 1970 Oct;26(4):832-41 [5528265.001]
  • [Cites] Anticancer Drugs. 2003 Mar;14(3):247-50 [12634620.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] Neurosurg Rev. 2006 Jan;29(1):36-40 [16220350.001]
  • (PMID = 19274122.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2651555
  • [Keywords] NOTNLM ; Anaplastic meningioma / Atypical meningioma / Extracranial metastasis
  •  go-up   go-down


5. Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G, Gutmann DH, Perry A: Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res; 2005 Aug 15;65(16):7121-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.
  • Although meningiomas are common central nervous system tumors, little is known about the genetic events responsible for malignant progression.
  • In this study, we employed gene expression profiling to identify transcripts whose expression was lost in anaplastic (WHO grade III) versus benign (WHO grade I) meningioma.
  • Approximately 40% of genes down-regulated in anaplastic meningioma were localized to chromosomes 1p and 14q.
  • One specific gene located at 14q11.2, NDRG2, was consistently down-regulated in grade III meningioma, a finding which we validated at both the transcript and protein levels in independent sets of clinically and pathologically diverse meningiomas.
  • Loss of NDRG2 expression was also seen in a subset of lower-grade meningiomas, including atypical meningiomas (WHO grade II) with clinically aggressive behavior.
  • Collectively, these data identify NDRG2 as the first specific candidate tumor suppressor gene on chromosome 14q that is inactivated during meningioma progression.
  • In addition, these findings highlight the utility of combining genomic, epigenetic, and expression data to identify clinically significant tumor biomarkers, and suggest that NDRG2 expression will be a useful and functionally relevant biomarker to predict aggressive behavior in patients with meningioma.
  • [MeSH-major] Genes, Tumor Suppressor. Meningeal Neoplasms / genetics. Meningioma / genetics. Proteins / genetics

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103061.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NDRG2 protein, human; 0 / Proteins; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


6. Lwu S, Starreveld YP, Branson J, Perry A: Anaplastic meningioma arising from a radiologically diagnosed arachnoid cyst: case report. Neurosurgery; 2010 Jul;67(1):212-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic meningioma arising from a radiologically diagnosed arachnoid cyst: case report.
  • OBJECTIVE AND IMPORTANCE: We report the first example of an anaplastic meningioma arising from an intracranial arachnoid cyst and discuss the diagnostic challenges of this case, including the useful role of genetic markers.
  • Histologic and immunohistochemical studies of the thickened portion initially suggested a metastatic carcinosarcoma, but fluorescence in situ hybridization (FISH) studies confirmed the diagnosis of anaplastic meningioma based on characteristic chromosomal deletions.
  • CONCLUSION: Malignant transformation of meningothelial elements in arachnoid cysts is an exceptionally rare complication that poses considerable diagnostic challenges.
  • [MeSH-major] Arachnoid Cysts / complications. Arachnoid Cysts / pathology. Meningeal Neoplasms / etiology. Meningeal Neoplasms / pathology. Meningioma / etiology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20559070.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Korenkov AI, Imhof HG, Brandner S, Taub E, Huguenin PU, Gaab MR, Yonekawa Y: Growth retardation and bilateral cataracts followed by anaplastic meningioma 23 years after high-dose cranial and whole-body irradiation for acute lymphoblastic leukemia: case report and review of the literature. J Neurooncol; 2005 Sep;74(2):195-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth retardation and bilateral cataracts followed by anaplastic meningioma 23 years after high-dose cranial and whole-body irradiation for acute lymphoblastic leukemia: case report and review of the literature.
  • We report a case of meningioma diagnosed 23 years after high-dose cranial and whole-body irradiation for the treatment of acute lymphocytic leukemia (ALL).
  • Radiation-induced meningiomas are more commonly malignant, more commonly multiple, and more likely to recur after resection than non-radiation-induced meningiomas.
  • Survivors of childhood ALL treated with high-dose cranial irradiation are at risk both for early radiation injury in radiosensitive organs, such as the lens and pituitary gland, and for the later development of a radiation-induced meningioma.
  • [MeSH-major] Cataract / etiology. Cranial Irradiation / adverse effects. Growth Disorders / etiology. Meningeal Neoplasms / etiology. Meningioma / etiology. Neoplasms, Radiation-Induced / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy


8. Puchner MJ, Hans VH, Harati A, Lohmann F, Glas M, Herrlinger U: Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol; 2010 Dec;21(12):2445-6
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab-induced regression of anaplastic meningioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21041375.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


9. Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A: Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology; 2007 Apr;27(2):114-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma.
  • Meningiomas represent the second most common central nervous system neoplasms in adults and account for 26% of all primary brain tumors.
  • Although most are benign, between 5% and 15% of meningiomas are atypical (grade II) whereas 1-2% are anaplastic meningiomas (grade III).
  • Although histological grade is the most relevant prognostic factor, there are some unusual cases in which establishing a diagnosis of high-grade meningioma following 2000 World Health Organization (WHO) histological criteria is extremely difficult.
  • Therefore, the aim of the present study was to evaluate the predictive value of Ki-67 labeling index and its contribution to current WHO classification in predicting tumor recurrence and overall survival in patients with high-grade meningiomas.
  • A total of 28 patients (with 16 atypical meningiomas and 12 anaplastic meningiomas) were evaluated for demographic, clinical, radiological and therapeutic variables, and for Ki-67 immunohistochemistry.
  • More importantly, this predictive value was maintained in both patients with atypical and patients with anaplastic meningioma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Ki-67 Antigen / metabolism. Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neuropathology. 2008 Feb;28(1):106-7 [18181839.001]
  • (PMID = 17494511.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


10. Shintaku M, Hashimoto K, Okamoto S: Intraventricular meningioma with anaplastic transformation and metastasis via the cerebrospinal fluid. Neuropathology; 2007 Oct;27(5):448-52
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraventricular meningioma with anaplastic transformation and metastasis via the cerebrospinal fluid.
  • We report a surgical case of intraventricular meningioma that arose in the trigone of the right lateral ventricle of a 61-year-old woman.
  • The tumor exhibited a histopathological appearance of transitional meningioma without cellular atypism in the original specimen, but in the metastatic nodules in the fourth ventricle and spinal subarachnoid space the histopathology was that of typical anaplastic meningioma.
  • Only four cases of anaplastic intraventricular meningioma that developed metastasis via the CSF have been reported.
  • This report presents the fifth case, which is also the second case in which progression from ordinary low-grade meningioma to anaplastic meningioma was demonstrated histopathologically.
  • [MeSH-major] Cerebral Ventricles / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018478.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


11. Yang SY, Park CK, Park SH, Kim DG, Chung YS, Jung HW: Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry; 2008 May;79(5):574-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features.
  • OBJECTIVES: To evaluate patient outcome and investigate the prognostic factors of high-grade meningiomas by adopting the 2000 World Health Organization (WHO) classification system.
  • METHODS: Between 1986 and 2004, 74 patients were diagnosed with high-grade meningioma: 33 with atypical and 41 with anaplastic meningioma.
  • RESULTS: Forty of 74 meningiomas were reclassified as atypical meningioma and 24 as anaplastic meningioma.
  • Overall and recurrence-free survivals were significantly longer in patients with atypical than in those with anaplastic meningioma: 142.5 versus 39.8 months and 138.5 versus 32.2 months, respectively (p<0.001).
  • In patients with atypical meningiomas, brain invasion and adjuvant radiotherapy were not associated with survival; however, in the brain invasion subgroup, adjuvant radiotherapy improved patients' survival.
  • In patients with anaplastic meningioma, the prognostic factors were brain invasion, adjuvant radiotherapy, malignant progression, p53 overexpression and extent of resection.
  • The p53 overexpression was the only factor associated with malignant progression (p = 0.009).
  • CONCLUSIONS: The 2000 WHO classification has identified the truly aggressive meningiomas better than did the previous criteria.
  • A precise meningioma grading system may help to avoid over-treatment of patients with an atypical meningioma as, once the tumour has "declared itself" by recurrence and histological features, it becomes a tumour that is poorly amenable to current therapies.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Adult. Aged. Brain / pathology. Combined Modality Therapy. Cranial Irradiation. Disease Progression. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic / genetics. Humans. Ki-67 Antigen / genetics. Korea. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / classification. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome. Tumor Suppressor Protein p53 / genetics. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17766430.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


12. Bollag RJ, Vender JR, Sharma S: Anaplastic meningioma: progression from atypical and chordoid morphotype with morphologic spectral variation at recurrence. Neuropathology; 2010 Jun;30(3):279-87
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic meningioma: progression from atypical and chordoid morphotype with morphologic spectral variation at recurrence.
  • The current WHO 2007 classification divides meningiomas into a 3-grade prognostic hierarchy.
  • Recent literature evokes two pathways to disease progression in meningiomas akin to a comparable paradigm in gliomas, but without similar prognostic connotation: de novo anaplastic meningioma (better prognosis), and transformed meningioma (worse prognosis).
  • We present two adult cases of transformed meningiomas that display a spectrum of morphologic progression.
  • Case 1 at presentation showed a random admixture of meningothelial, atypical and anaplastic meningioma.
  • The tumor recurred as anaplastic meningioma.
  • Case 2 presented as a chordoid meningioma, but recurred as anaplastic meningioma mainly at the invasive front in transition with residual chordoid pattern.
  • In accordance with the dire prognosis for anaplastic meningioma, both patients succumbed to their disease within 2 months of recurrence.
  • The present study highlights two main points: First, that proper recognition of focal high-grade areas in a heterogeneous low-grade meningioma (case 1) provides critical morphologic clues to spatial histologic progression and predicts aggressive biologic behavior, as evidenced by progression to frankly anaplastic meningioma at recurrence.
  • Second, the presence of papillary in addition to anaplastic areas, in the recurrence of a previously diagnosed chordoid meningioma supports the ostensibly heightened transforming potential of grade II meningiomas, but also reflects on the morphologic heterogeneity of high-grade meningiomas, and their potentially diverse pathways of progression.
  • We propose that grading of meningiomas as outlined by WHO is of more critical prognostic import than histologic sub-typing, and must include a thorough survey of the tumor-brain interface.
  • Future molecular genetic correlates, akin to those characterized in gliomas, could help stratify prognostic subcategories to refine meningioma grading, and govern optimal therapeutic strategies.
  • [MeSH-major] Choroid Plexus Neoplasms / diagnosis. Choroid Plexus Neoplasms / pathology. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / pathology. Meningioma / diagnosis. Meningioma / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Fatal Outcome. Humans. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19780983.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


13. Martin-Vaquero P, Da Costa RC, Aeffner F, Oglesbee MJ, Echandi RL: Imaging diagnosis--Hemorrhagic meningioma. Vet Radiol Ultrasound; 2010 Mar-Apr;51(2):165-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging diagnosis--Hemorrhagic meningioma.
  • The histologic diagnosis was anaplastic meningioma with acute hemorrhage.
  • These findings document an unusual appearance of a meningioma in MR images due to intratumoral hemorrhage.
  • [MeSH-major] Dog Diseases / diagnosis. Intracranial Hemorrhages / veterinary. Meningeal Neoplasms / veterinary. Meningioma / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20402404.001).
  • [ISSN] 1058-8183
  • [Journal-full-title] Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
  • [ISO-abbreviation] Vet Radiol Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Sanz Esponera J: [Meningiomas: new prognostic factors]. An R Acad Nac Med (Madr); 2007;124(2):319-32; discussion 330-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Meningiomas: new prognostic factors].
  • [Transliterated title] Meningiomas. nuevos factores pronósticos.
  • Meningiomas are still defined as benignant tumours although 25% of those tumours will have local recurrance in the follow-up period.
  • The WHO (2000) classification divides meningiomas in three goups: Grade 1 for conventional meningioma.
  • Grade 2 for atypical meningioma and Grade 3 for Anaplastic meningioma.
  • Specific histological variants of meningiomas have been included in grade 2 tumours.
  • Clear cell, rabdoid and papillary meningiomas.
  • We obtained 250 meningiomas from our files and we analyzed 30 inmunohistochemical markers.
  • Several markers can be actually used as prognostic indicators in meningiomas and may allow a more individualized management of patients.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18069599.001).
  • [ISSN] 0034-0634
  • [Journal-full-title] Anales de la Real Academia Nacional de Medicina
  • [ISO-abbreviation] An R Acad Nac Med (Madr)
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


15. Qi ZG, Li YX, Wang Y, Geng DY, Li KC, Shen TZ, Chen XR: Lipid signal in evaluation of intracranial meningiomas. Chin Med J (Engl); 2008 Dec 5;121(23):2415-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipid signal in evaluation of intracranial meningiomas.
  • BACKGROUND: Using magnetic resonance imaging, diagnosis of malignant meningioma from benign meningioma with atypical features is uncertain.
  • We evaluated the value of lipid signal in differentiating intracranial meningiomas.
  • RESULTS: Twenty-nine meningiomas were histologically benign (eleven meningothelial, thirteen fibrous, four transitional and one microcystic), three were atypical, and two were anaplastic.
  • Lipid signal was detected in ten cases: two anaplastic, three atypical, two fibrous and three meningothelial meningiomas.
  • With creatinine peak in the normal white matter chosen as internal standard, lipid/creatinine ratios of anaplastic, atypical and benign meningiomas were 0.844 +/- 0.027 (range from 0.725 to 0.994), 0.465 +/- 0.023 (range from 0.239 to 0.724), and 0.373 +/- 0.016 (range from 0.172 to 0.571) respectively.
  • Highly significant differences were noted between anaplastic and the other two subtypes.
  • Patchy necrosis was observed in anaplastic meningioma, while focal necrosis was noted in atypical meningioma with HE stain.
  • KP-1 stain demonstrated histocytes containing lipids in the necrotic region of anaplastic and atypical meningioma.
  • CONCLUSION: The lipid signal at 1.3 ppm is a useful marker in evaluating the malignancy of intracranial meningiomas, especially in the differential diagnosis of anaplastic meningioma.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102960.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Engenhart-Cabillic R, Farhoud A, Sure U, Heinze S, Henzel M, Mennel HD, Bertalanffy H: Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment. Strahlenther Onkol; 2006 Nov;182(11):641-6
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
  • BACKGROUND AND PURPOSE: Although meningiomas are typically benign, they occasionally behave in an aggressive fashion and carry a less favorable prognosis.
  • PATIENTS AND METHODS: 16 patients with atypical meningiomas (n = 11) and anaplastic meningiomas (n = 5) were treated in the Departments of Neurosurgery and Radiation Oncology at the University Hospital of Philipps University Marburg, Germany, between 1997 and 2003.
  • Patients with atypical meningioma received radiotherapy only for the recurrent disease.
  • Radiographic findings suggestive of aggressiveness were observed mostly with WHO grade III meningiomas.
  • By comparing the proliferation rate in four cases with atypical meningioma operated twice, the recurrent tumor had a higher proliferation rate than the first tumor in three cases.
  • A special proliferation pattern was noticed in MIB-1 with anaplastic meningiomas.
  • There was no mortality among patients with atypical meningioma, while four out of five patients with anaplastic meningioma died during follow-up.
  • CONCLUSION: Considering the higher rate of recurrence in aggressive meningiomas even after radical surgical excision and the possibility that the recurrent tumor is more aggressive than the original one, surgery should be combined with postoperative fractionated radiotherapy to improve local tumor control.
  • The peculiar focal expression patterns of anaplastic meningioma in MIB-1 might be a marker of such malignant development.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / surgery. Meningioma / radiotherapy. Meningioma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17072521.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen
  •  go-up   go-down


17. Kunishio K, Kobayashi K, Kagawa M, Makabe T, Matsumoto A, Matsumoto Y: [A case of malignant meningioma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene]. Gan To Kagaku Ryoho; 2007 Feb;34(2):265-8
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant meningioma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene].
  • We report a case with malignant meningioma in which new preliminary treatment trial was performed by chemotherapy using anti-cancer drugs selected on the basis of multidrug resistance gene mRNA expression, such as MDR1, MGMT, MRP1, MRP2, MXR1, and DNA topoisomerase II alpha, from RT-PCR assay.
  • A 43-year-old female had been operated for parasagittal anaplastic meningioma three times because of recurrences. partial removal of tumor was performed at the 3rd operation.
  • Preliminary individual adjuvant chemotherapy based on mRNA expression of drug-resistance gene is available for the treatment of recurrent malignant meningioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301541.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Membrane Transport Proteins; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; 0 / multidrug resistance-associated protein 2; BZ114NVM5P / Mitoxantrone; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


18. Pelz AF, Klawunde P, Skalej M, Wieacker P, Kirches E, Schneider T, Mawrin C: Novel chromosomal aberrations in a recurrent malignant meningioma. Cancer Genet Cytogenet; 2007 Apr 1;174(1):48-53
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel chromosomal aberrations in a recurrent malignant meningioma.
  • The molecular basis of tumorigenesis and tumor progression in meningiomas is not fully understood.
  • Here we present results of conventional cytogenetic, fluorescence in situ hybridization (FISH), and comparative genetic hybridization (CGH) analyses in a patient with recurrent anaplastic meningioma.
  • We found complex aberrant karyotype alterations previously described in anaplastic meningiomas, such as 1p, 14q aberration, and a possibly tetraploid karyotype.
  • Our findings of several previously unreported cytogenetic alterations suggest that complex karyotype alterations are a characteristic feature in anaplastic meningiomas.
  • High chromosomal complexity might be associated with a highly aggressive meningioma phenotype.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17350466.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Zhao X, Sun JL, Wang ZG, Zhang TG, Wang CW, Ji Y: Clinical analysis for an unusual large cystic meningioma: case report and review of the literature. Clin Neurol Neurosurg; 2008 Jun;110(6):605-8
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical analysis for an unusual large cystic meningioma: case report and review of the literature.
  • The authors report the case of a 17-year-old boy with an unusual large cystic meningioma (Nauta type II) in the right hemisphere.
  • Histological examination displayed an anaplastic meningioma, of which the cyst wall also consisted of meningioma tissue.
  • To the best of the authors' knowledge, such an unusual case of cystic meningioma has not been reported.
  • The authors review the literature with reference to intratumoral cyst associated with meningiomas, analyze the unusual imaging appearances of this patient, and explore the mechanism of cyst formation.
  • The mechanism of cyst formation associated with meningiomas is not perfectly understood.
  • [MeSH-major] Cysts / pathology. Cysts / surgery. Meningioma / pathology. Meningioma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384935.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


20. Lau EW, Drummond KJ, Ware RE, Drummond E, Hogg A, Ryan G, Grigg A, Callahan J, Hicks RJ: Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. J Clin Neurosci; 2010 Jan;17(1):43-9
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Final malignant pathology included 11 glioma (eight low-grade, three high grade), two lymphoma, one olfactory ganglioneuroblastoma, one anaplastic meningioma.
  • FET PET is more accurate than FDG PET for detecting malignant brain lesions, especially low-grade gliomas.
  • [MeSH-minor] Adult. Aged. Brain / pathology. Brain / physiopathology. Brain / radionuclide imaging. Diagnosis, Differential. Diagnostic Errors / prevention & control. Female. Glioma / metabolism. Glioma / pathology. Glioma / radionuclide imaging. Humans. Lymphoma / metabolism. Lymphoma / pathology. Lymphoma / radionuclide imaging. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Reproducibility of Results. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20004582.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / O-(2-((18)F)fluoroethyl)-L-tyrosine; 0 / Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 42HK56048U / Tyrosine
  •  go-up   go-down


21. Modha A, Gutin PH: Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery; 2005 Sep;57(3):538-50; discussion 538-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of atypical and anaplastic meningiomas: a review.
  • Atypical and anaplastic meningiomas are uncommon tumors with a poorer prognosis than benign meningiomas.
  • Both tumors are rare and are often integrated with benign meningiomas when treatments are evaluated.
  • In addition, because there has not been one histopathological classification scheme for atypical and anaplastic meningiomas in the past, there are numerous inconsistencies in the literature.
  • Malignant progression with accumulation of mutations in a benign meningioma can result in an atypical and/or anaplastic meningioma.
  • [MeSH-major] Brain Neoplasms / therapy. Meningeal Neoplasms / therapy. Meningioma / therapy
  • [MeSH-minor] Algorithms. Anaplasia / diagnosis. Anaplasia / metabolism. Anaplasia / therapy. Disease Progression. Drug Therapy / methods. Humans. Immunohistochemistry / methods. Magnetic Resonance Imaging. Radiosurgery. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16145534.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Number-of-references] 65
  •  go-up   go-down


22. Plotkin M, Amthauer H, Eisenacher J, Wurm R, Michel R, Wust P, Stockhammer F, Röttgen R, Gutberlet M, Ruf J, Felix R: Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours. Neuroradiology; 2005 Jan;47(1):18-26
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours.
  • The value of single-photon emission tomography (SPECT) using iodine-123-alpha-methyl-tyrosine (IMT) for the diagnosis of recurrent or residual gliomas is well established.
  • The study included 22 patients with suspected recurrent intracranial tumours of non-astrocytic origin (12 brain metastases, one supratentorial primitive neuroendocrine tumour (PNET), one rhabdoid tumour, two clivus chordomas, three ependymomas, two pituitary tumours, one anaplastic meningioma) who had previously been treated by surgery and/or radio/chemotherapy.
  • [MeSH-minor] Adolescent. Adult. Aged. Chordoma / diagnostic imaging. Ependymoma / diagnostic imaging. False Negative Reactions. False Positive Reactions. Female. Follow-Up Studies. Glioma / diagnostic imaging. Humans. Magnetic Resonance Imaging. Male. Meningioma / diagnostic imaging. Middle Aged. Neuroendocrine Tumors / diagnostic imaging. Pituitary Neoplasms / diagnostic imaging. Retrospective Studies. Rhabdoid Tumor / diagnostic imaging. Sensitivity and Specificity. Supratentorial Neoplasms / diagnostic imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2001 Apr;42(4):579-85 [11337545.001]
  • [Cites] Acta Radiol. 1989 Mar-Apr;30(2):121-8 [2493795.001]
  • [Cites] Ann Nucl Med. 2002 Nov;16(7):503-6 [12508845.001]
  • [Cites] J Neurooncol. 2004 Oct;70(1):49-58 [15527107.001]
  • [Cites] AJR Am J Roentgenol. 1994 Dec;163(6):1459-65 [7992747.001]
  • [Cites] Eur J Nucl Med. 1998 Feb;25(2):177-81 [9473267.001]
  • [Cites] J Nucl Med. 2000 Nov;41(11):1793-800 [11079485.001]
  • [Cites] Neuroimaging Clin N Am. 1999 Nov;9(4):801-19 [10517946.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):396-404 [11786566.001]
  • [Cites] Eur J Nucl Med. 1999 Feb;26(2):144-51 [9933348.001]
  • [Cites] Semin Oncol. 1994 Apr;21(2):162-71 [8153662.001]
  • [Cites] Nuklearmedizin. 1995 Apr;34(2):71-5 [7761277.001]
  • [Cites] Semin Nucl Med. 2003 Apr;33(2):148-62 [12756647.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Feb;17 (2):345-53 [8938309.001]
  • [Cites] J Nucl Med. 1989 Jan;30(1):110-2 [2783455.001]
  • [Cites] J Nucl Med. 1998 Oct;39(10 ):1736-43 [9776279.001]
  • [Cites] J Nucl Med. 1998 Jan;39(1):23-7 [9443732.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 May-Jun;14 (3):524-7 [8517335.001]
  • [Cites] Nucl Med Commun. 1996 Mar;17 (3):197-8 [8692485.001]
  • [Cites] J Nucl Med. 1997 Apr;38(4):517-22 [9098193.001]
  • [Cites] Radiology. 1993 Jan;186(1):37-44 [8416584.001]
  • [Cites] Acta Radiol. 1990 Sep;31(5):417-29 [2261284.001]
  • [Cites] Radiology. 2003 Jan;226(1):181-7 [12511688.001]
  • [Cites] Nuklearmedizin. 1997 Mar;36(2):36-41 [9148271.001]
  • [Cites] J Nucl Med. 2004 Mar;45(3):374-81 [15001676.001]
  • [Cites] J Comput Assist Tomogr. 1983 Dec;7(6):1062-6 [6415134.001]
  • [Cites] Neurosurgery. 1993 Jul;33(1):28-33 [8355844.001]
  • [Cites] AJR Am J Roentgenol. 1988 Jan;150(1):189-97 [3257119.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):43-52 [10924970.001]
  • [Cites] Curr Opin Oncol. 1994 May;6(3):254-61 [8080854.001]
  • [Cites] J Nucl Med. 2004 Apr;45(4):579-86 [15073253.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):842-54 [12377338.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2252-9 [10873075.001]
  • [Cites] J Nucl Med. 1998 May;39(5):778-85 [9591574.001]
  • [Cites] Nucl Med Commun. 1996 Jul;17 (7):609-15 [8843121.001]
  • [Cites] J Neurosurg. 2003 May;98 (5):1056-64 [12744366.001]
  • [Cites] Nuklearmedizin. 2002;41(4):191-6 [12224403.001]
  • [Cites] Ann Neurol. 1991 Apr;29(4):347-55 [1929205.001]
  • [Cites] J Nucl Med. 1990 Mar;31(3):281-6 [2155314.001]
  • (PMID = 15630586.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Methyltyrosines; 0 / Radiopharmaceuticals; A77N8J5H5T / 3-iodo-alpha-methyltyrosine
  •  go-up   go-down


23. Liu Y, Liu M, Li F, Wu C, Zhu S: Malignant meningiomas: a retrospective study of 22 cases. Bull Cancer; 2007 Oct;94(10):E27-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant meningiomas: a retrospective study of 22 cases.
  • Malignant (anaplastic) meningioma constitutes a rare subset of meningioma.
  • The aim of the study was to study clinical features and management of malignant meningiomas.
  • Twenty-two patients with malignant meningiomas were surgically treated in our department between January 1986 and January 2005 in Qilu hospital, and we reviewed each patient's clinical records, radiological findings, operative reports, and pathological examinations.
  • Surgical resection and adjuvant radiotherapy are the main treatments for malignant meningiomas, and the degree of tumor removal is the leading factor determining postoperative recurrence and survival.
  • [MeSH-major] Meningeal Neoplasms. Meningioma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964977.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


24. Garcia-Conde M, Roldan-Delgado H, Martel-Barth-Hansen D, Manzano-Sanz C: Anaplastic transformation of an atypical intraventricular meningioma with metastases to the liver: case report. Neurocirugia (Astur); 2009 Dec;20(6):541-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic transformation of an atypical intraventricular meningioma with metastases to the liver: case report.
  • OBJECTIVE: Malignant intraventricular meningiomas are very rare.
  • We present herein the first case of a malignant intraventricular meningioma with extraneural metastases.
  • Histological examination demonstrated an atypical meningioma.
  • Histological examination showed anaplastic meningioma.
  • Biopsy was consistent with liver metastases of a malignant meningioma.
  • The patient died of acute liver failure seven months after initial diagnosis.
  • CONCLUSION: Malignant intraventricular meningiomas are prone to recur and develop metastases, mainly through the CSF.
  • Therefore, when systemic deterioration occurs in a patient with a malignant intraventricular meningioma, metastases to extraneural organs such as the liver must be ruled out.
  • [MeSH-major] Anaplasia / pathology. Liver Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19967319.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


25. Adeolu AA, Sutherland GR: Intraoperative magnetic resonance imaging and meningioma surgery. West Afr J Med; 2006 Jul-Sep;25(3):174-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative magnetic resonance imaging and meningioma surgery.
  • OBJECTIVE: To determine if intraoperative magnetic resonance imaging improves surgical resection and postoperative outcome of intracranial meningioma.
  • METHOD: Intraoperative Magnetic Resonance Imaging (iMRI) was used to evaluate patients with meningioma undergoing surgery.
  • Extent of surgical resection was graded using Simpson grading system for meningioma.
  • Two of these patients had anaplastic meningioma.
  • [MeSH-major] Magnetic Resonance Imaging. Meningeal Neoplasms / surgery. Meningioma / surgery. Surgery, Computer-Assisted

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17191414.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


26. Widdel L, Kleinschmidt-DeMasters BK, Kindt G: Tumor-to-tumor metastasis from hematopoietic neoplasms to meningiomas: report of two patients with significant cerebral edema. World Neurosurg; 2010 Jul;74(1):165-71
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-to-tumor metastasis from hematopoietic neoplasms to meningiomas: report of two patients with significant cerebral edema.
  • OBJECTIVE: To report two examples of benign meningiomas in which metastatic tumor deposits from the patient's hematopoietic neoplasm to the meningioma caused significant peritumoral edema, necessitating semiemergent surgical resection.
  • Clinical suspicion in both patients was an atypical or anaplastic meningioma due to the edema.
  • RESULTS: One patient had multiple myeloma associated with extensive necrosis within his otherwise benign convexity meningioma; first diagnosis of his IgG, kappa-restricted plasma cell dyscrasia was made from this tumor-to-tumor meningioma specimen.
  • The second patient carried a diagnosis of marginal zone lymphoma but then presented 5 years later with symptoms referable to a large dural-based mass with significant surrounding edema, prompting surgical removal.
  • Dural marginal zone lymphoma was identified within epidural, intradural, and subdural spaces, in the same location as an underlying benign meningioma.
  • CONCLUSIONS: Although rare, neurosurgeons should be aware of the entity of tumor-to-tumor metastasis as, in large series, meningiomas are the third most frequent recipient tumor type and pituitary adenomas, the fifth most frequent, probably reflecting their rich vascularity.
  • [MeSH-major] Brain Edema / etiology. Image Processing, Computer-Assisted. Lymphoma, B-Cell, Marginal Zone / diagnosis. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / secondary. Meningioma / diagnosis. Multiple Myeloma / diagnosis. Multiple Myeloma / secondary. Neoplasms, Second Primary / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Brain / pathology. Brain / surgery. Diagnosis, Differential. Female. Humans. Male. Meninges / pathology. Meninges / surgery. Middle Aged

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21300009.001).
  • [ISSN] 1878-8769
  • [Journal-full-title] World neurosurgery
  • [ISO-abbreviation] World Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Combs SE, Edler L, Burkholder I, Rieken S, Habermehl D, Jäkel O, Haberer T, Unterberg A, Wick W, Debus J, Haselmann R: Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: the MARCIE trial. BMC Cancer; 2010 Nov 09;10:615
Hazardous Substances Data Bank. CARBON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: the MARCIE trial.
  • BACKGROUND: Treatment standard for patients with atypical or anaplastic meningioma is neurosurgical resection.
  • However, meningiomas are known to be radioresistant tumors, and radiation doses of 60 Gy or higher have been shown to be necessary for tumor control.
  • Moreover, in comparison to photons, carbon ions offer an increased relative biological effectiveness (RBE), which can be calculated between 2 and 5 depending on the cell line as well as the endpoint analyzed.First data obtained within the Phase I/II trial performed at GSI in Darmstadt on carbon ion radiotherapy for patients with high-risk meningiomas has shown safety, and treatment results are promising.
  • METHODS/DESIGN: The Phase II-MARCIE-Study will evaluate a carbon ion boost applied to the macroscopic tumor in conjunction with photon radiotherapy in patients with atypical meningiomas after incomplete resection or biopsy.Primary endpoint is progression-free survival, secondary endpoints are overall survival, safety and toxicity.
  • DISCUSSION: Based on published data on the treatment of atypical meningiomas with carbon ions at GSI, the present study will evaluate this treatment concept in a larger patient population and will compare outcome to current standard photon treatment.
  • [MeSH-major] Carbon / therapeutic use. Ions / therapeutic use. Meningioma / radiotherapy. Meningioma / surgery

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2000 Jun;48(2):151-60 [11083080.001]
  • [Cites] Radiother Oncol. 2010 Apr;95(1):54-9 [20189258.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):501-4 [3042721.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):2-12 [1641106.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):817-22 [8598358.001]
  • [Cites] Acta Neurochir (Wien). 1995;135(3-4):171-8 [8748810.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):809-16 [15708260.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):767-73 [16306156.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):641-6 [17072521.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):171-7 [17056193.001]
  • [Cites] J Clin Oncol. 2007 Mar 10;25(8):953-64 [17350944.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):449-57 [17363188.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Br J Neurosurg. 2007 Dec;21(6):588-92 [18071986.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1388-93 [18294779.001]
  • [Cites] Int J Radiat Biol. 2009 Feb;85(2):126-37 [19280465.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):803-8 [11395250.001]
  • (PMID = 21062428.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT01166321
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ions; 7440-44-0 / Carbon
  • [Other-IDs] NLM/ PMC2996393
  •  go-up   go-down


28. Yamamoto T, Nakai K, Matsumura A: Boron neutron capture therapy for glioblastoma. Cancer Lett; 2008 Apr 18;262(2):143-52
Hazardous Substances Data Bank. BORON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent clinical studies of BNCT have focused on high-grade glioma and cutaneous melanoma; however, cerebral metastasis of melanoma, anaplastic meningioma, head and neck tumor, and lung and liver metastasis have been investigated as potential candidates for BNCT.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313207.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] N9E3X5056Q / Boron
  • [Number-of-references] 77
  •  go-up   go-down


29. Chung SB, Kim CY, Park CK, Kim DG, Jung HW: Falx meningiomas: surgical results and lessons learned from 68 cases. J Korean Neurosurg Soc; 2007 Oct;42(4):276-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Falx meningiomas: surgical results and lessons learned from 68 cases.
  • OBJECTIVE: The purpose of this study was to review the characteristics of falcine meningioma retrospectively and to identify the parameters associated with tumor recurrence.
  • Falcine meningiomas were classified by location as anterior, middle, or posterior as described for parasagittal meningiomas.
  • RESULTS: Of the 795 meningioma patients treated between 1990 and 2004 at the authors' institution, 68 patients with meningiomas arising from the falx underwent craniotomies.
  • Locations of falcine meningioma were; the anterior third in 33 cases, middle in 20, and posterior in 15.
  • There were four patients with a high grade tumor-three atypical and one anaplastic meningioma.
  • CONCLUSION: Falcine meningioma accounted for 8.5% of intracranial meningiomas and the transitional meningioma was the most common subtype of falcine meningioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2006 Jul;105(1):60-4 [16871881.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95 [16331155.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Neurosurgery. 2002 Dec;51(6):1432-39; discussion 1439-40 [12445348.001]
  • [Cites] Surg Neurol. 1984 May;21(5):427-35 [6710323.001]
  • [Cites] Neurochirurgia (Stuttg). 1979 Mar;22(2):47-51 [440515.001]
  • [Cites] J Neurosurg. 2004 Mar;100(3):422-30 [15035277.001]
  • [Cites] Clin Neurosurg. 1993;40:321-83 [8111990.001]
  • (PMID = 19096556.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2588203
  • [Keywords] NOTNLM ; Falcine meningioma / Histological subtype / Surgical results
  •  go-up   go-down


30. Gupta R, Suri V, Jain A, Sharma MC, Sarkar C, Singh MM, Joshi NP, Puri T, Julka PK: Anaplastic meningioma in an adolescent: a report of a rare case and brief review of literature. Childs Nerv Syst; 2009 Feb;25(2):241-5
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic meningioma in an adolescent: a report of a rare case and brief review of literature.
  • OBJECTIVE: Anaplastic meningioma is an uncommon neoplasm in childhood and adolescence.
  • Due to the rarity, treatment options for anaplastic meningioma in this age group are not clearly outlined.
  • Histopathological examination of the tumor showed features of an anaplastic meningioma.
  • CONCLUSION: Anaplastic meningioma is extremely rare in children.
  • Extensive sampling is required to recognize the meningothelial nature of the tumor and immunohistochemistry helps in making an accurate diagnosis in such cases.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Meningioma / diagnosis. Meningioma / therapy
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Mucin-1 / analysis. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] J Child Neurol. 2006 Jan;21(1):31-6 [16551450.001]
  • [Cites] Pediatr Neurosurg. 2005 Jan-Feb;41(1):1-7 [15886506.001]
  • [Cites] J Neurosurg. 2004 Feb;100(2 Suppl Pediatrics):179-82 [14758946.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Expert Rev Neurother. 2006 Oct;6(10):1447-64 [17078786.001]
  • [Cites] Childs Brain. 1980;7(1):43-56 [7428495.001]
  • [Cites] J Neurosurg. 1996 May;84(5):733-6 [8622144.001]
  • [Cites] Childs Nerv Syst. 1986;2(3):160-1 [3779674.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):157-65 [16193387.001]
  • [Cites] Neurol Med Chir (Tokyo). 1978;18(1 Pt 1):119-27 [77488.001]
  • (PMID = 18769931.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mucin-1; 0 / Vimentin
  • [Number-of-references] 11
  •  go-up   go-down


31. García-Purriños FJ, Rosell Cervilla A, Lemberg P, Calvo Moya J: [Nasal malignant meningioma]. Acta Otorrinolaringol Esp; 2005 Oct;56(8):373-5
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nasal malignant meningioma].
  • [Transliterated title] Meningioma maligno nasal. manejo de un caso y revisión de la literatura.
  • Extracraneal meningiomas represent 2% of all meningiomas and can appear in different locations including paranasales sinuses.
  • There are no statistics regarding ectopic malignant meningiomas, but they are considered extremely rare.
  • We present a patient with a malignant meningioma of the etmoidal sinus, his treatment and the evolution over a five year period.
  • [MeSH-major] Meningioma / pathology. Nose Neoplasms / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285437.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


32. Etienne-Mastroianni B, Girard N, Ginguene C, Tronc F, Vasiljevic A, Vallee B, Cordier JF: [Pulmonary metastases from malignant meningioma]. Rev Mal Respir; 2010 Sep;27(7):764-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary metastases from malignant meningioma].
  • [Transliterated title] Métastases pulmonaires de méningiome malin.
  • INTRODUCTION: Pulmonary metastases from meningioma are rare and present with specific clinical and radiological features.
  • The diagnostic and therapeutic management of metastatic meningioma illustrate the concept of orphan thoracic oncology.
  • CASE REPORT: We report the case of a 58-year-old male, former smoker, with a previous history of atypical meningioma and resected lung adenocarcinoma.
  • Pathological examination of metastasectomy specimens revealed metastatic malignant meningioma.
  • CONCLUSIONS: Pulmonary metastases may occur in malignant meningioma.
  • [MeSH-major] Lung Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / secondary

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 SPLF. Published by Elsevier Masson SAS. All rights reserved.
  • (PMID = 20863979.001).
  • [ISSN] 1776-2588
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


33. Baia GS, Dinca EB, Ozawa T, Kimura ET, McDermott MW, James CD, VandenBerg SR, Lal A: An orthotopic skull base model of malignant meningioma. Brain Pathol; 2008 Apr;18(2):172-9
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An orthotopic skull base model of malignant meningioma.
  • Meningioma tumor growth involves the subarachnoid space that contains the cerebrospinal fluid.
  • Modeling tumor growth in this microenvironment has been associated with widespread leptomeningeal dissemination, which is uncharacteristic of human meningiomas.
  • We report the development and characterization of a reproducible orthotopic skull-base meningioma model in athymic mice using the IOMM-Lee cell line.
  • These tumors had histopathologic characteristics of anaplastic meningiomas including high cellularity, nuclear pleomorphism, cellular pattern loss, necrosis and conspicuous mitosis.
  • Similar to human meningiomas, considerable invasion of the dura and skull and some invasion of adjacent brain along perivascular tracts were observed.
  • The pattern of hypoxia was also similar to human malignant meningiomas.
  • Thus, we describe a malignant meningioma model system that will be useful for investigating the biology of meningiomas and for preclinical assessment of therapeutic agents.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Transplantation / methods. Skull Base Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18093250.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / 1R03NS054829-01; United States / NCI NIH HHS / CA / P50CA097257
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Tumor Suppressor Proteins; 147336-22-9 / Green Fluorescent Proteins; 298-93-1 / thiazolyl blue; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


34. Eom KS, Kim HS, Kim TY, Kim JM: Intraventricular Malignant Meningioma with CSF-Disseminated Spinal Metastasis : Case Report and Literature Review. J Korean Neurosurg Soc; 2009 Apr;45(4):256-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraventricular Malignant Meningioma with CSF-Disseminated Spinal Metastasis : Case Report and Literature Review.
  • The tumor was histologically atypical meningioma.
  • After 26 months, there were recurrences of intraventricular meningioma.
  • Complete resection of the tumor and adjuvant radiation therapy were performed, and the histological diagnosis was malignant meningioma.
  • We describe an unusual case of intraventricular malignant meningioma with cerebrospinal fluid-disseminated spinal metastases with review of the clinical courses of previous reports.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1989 Sep;32(3):213-8 [2772810.001]
  • [Cites] Neuropathology. 2007 Oct;27(5):448-52 [18018478.001]
  • [Cites] Spine (Phila Pa 1976). 2006 Dec 15;31(26):E1006-10 [17172988.001]
  • [Cites] Clin Neuropathol. 1985 Sep-Oct;4(5):214-9 [4064387.001]
  • [Cites] Br J Radiol. 1995 Apr;68(808):428-30 [7795983.001]
  • [Cites] Br J Radiol. 1994 Mar;67(795):223-43 [8130994.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(10):1172-7; discussion 1177-8 [8955436.001]
  • (PMID = 19444356.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2682126
  • [Keywords] NOTNLM ; Intraventricular neoplasms / Malignant meningioma / Spinal metastases
  •  go-up   go-down


35. Boskos C, Feuvret L, Noel G, Habrand JL, Pommier P, Alapetite C, Mammar H, Ferrand R, Boisserie G, Mazeron JJ: Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):399-406
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma.
  • PURPOSE: To evaluate retrospectively the efficacy of conformal fractionated radiotherapy combining proton and photon beams after primary surgery for treatment of atypical and malignant meningiomas.
  • PATIENTS AND METHODS: Between September 1999 and October 2006, 24 patients (12 male, 12 female) with histopathologically proven meningioma (atypical 19, malignant 5) received postoperative combined radiotherapy with a 201-MeV proton beam at the Centre Protontherapie d'Orsay and a high-energy photon beam.
  • The overall mean local relapse-free interval was 27.2 (10-50) months, 28.3 (10-50) months for atypical meningioma and 23 (13-33) months for malignant meningioma.
  • CONCLUSIONS: Postoperative combination of conformal radiotherapy with protons and photons for atypical and malignant meningiomas is a well-tolerated treatment producing long-term tumor stabilization.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Photons / therapeutic use. Protons / therapeutic use. Radiotherapy, Conformal / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19203844.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


36. Yang X, Gao X, Wang S: Primary mediastinal malignant meningioma. Eur J Cardiothorac Surg; 2009 Jul;36(1):217-8
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal malignant meningioma.
  • Primary ectopic meningiomas are extremely rare tumors of controversial origin and they are usually limited to the head and neck region.
  • There has not been any official report regarding primary mediastinal malignant meningioma until today.
  • Because of its rarity and potential value, we report here a case of primary mediastinal malignant meningioma, which turns out to be the first reported case of this type of meningioma.
  • The clinical features, treatment plans, pathological findings, as well as prognosis of a case of primary mediastinal malignant meningioma were carefully analyzed and the literature on ectopic meningioma was reviewed.
  • The diagnosis of ectopic meningioma can only be established based on microscopic and immunohistochemical findings.
  • Surgery is the treatment of choice for ectopic meningioma and postoperative radiotherapy should be managed for patients with suspected invasive meningioma.
  • [MeSH-major] Mediastinal Neoplasms / radiography. Meningioma / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19410481.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


37. Pasquier D, Bijmolt S, Veninga T, Rezvoy N, Villa S, Krengli M, Weber DC, Baumert BG, Canyilmaz E, Yalman D, Szutowicz E, Tzuk-Shina T, Mirimanoff RO, Rare Cancer Network: Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network. Int J Radiat Oncol Biol Phys; 2008 Aug 1;71(5):1388-93
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network.
  • PURPOSE: To retrospectively analyze and assess the outcomes and prognostic factors in a large number of patients with atypical and malignant meningiomas.
  • METHODS AND MATERIALS: Ten academic medical centers participating in this Rare Cancer Network contributed 119 cases of patients with atypical or malignant meningiomas treated with external beam radiotherapy (EBRT) after surgery or for recurrence.
  • Eligibility criteria were histologically proven atypical or anaplastic (malignant) meningioma (World Health Organization Grade 2 and 3) treated with fractionated EBRT after initial resection or for recurrence, and age >18 years.
  • Surgery was macroscopically complete (Simpson Grades 1-3) in 71% of patients; histology was atypical and malignant in 69% and 31%, respectively.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294779.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


38. van der Meij JJ, Boomars KA, van den Bosch JM, van Boven WJ, de Bruin PC, Seldenrijk CA: Primary pulmonary malignant meningioma. Ann Thorac Surg; 2005 Oct;80(4):1523-5
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary malignant meningioma.
  • Primary pulmonary meningiomas are relatively rare and mostly benign.
  • To exclude pulmonary metastasis of an intracranial meningioma, imaging studies of the brain should be performed.
  • We believe that only one primary pulmonary malignant meningioma in which a metastasis from the brain was excluded has been reported.
  • In this report we describe a second case with malignant features.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Bronchial Neoplasms / pathology. Meningioma / diagnosis. Meningioma / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Esophageal Neoplasms / pathology. Female. Humans. Liver Neoplasms / secondary. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Neoplasm Invasiveness. Pleural Neoplasms / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181912.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


39. Khalatbari M, Borghei-Razavi H, Shayanfar N, Behzadi AH, Sepehrnia A: Collision tumor of meningioma and malignant astrocytoma. Pediatr Neurosurg; 2010;46(5):357-61
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of meningioma and malignant astrocytoma.
  • The pathology of tumors reported collision tumors composed of meningioma and malignant astrocytoma.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21389747.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


40. Cauley K, Jagjivan B, Khan A: Malignant meningioma: computed tomography and magnetic resonance imaging characteristics. Conn Med; 2005 Nov-Dec;69(10):629-32
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant meningioma: computed tomography and magnetic resonance imaging characteristics.
  • Malignant meningioma is a relatively rare subtype of meningioma demonstrating an aggressive growth pattern, distinct histologic features, and a propensity for recurrence following surgical resection.
  • There has been little consensus regarding imaging features of malignant meningioma, and typically the degree of tumor aggressiveness is determined by pathology.
  • Here we describe a case of malignant meningioma determined to be benign at initial biopsy.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381110.001).
  • [ISSN] 0010-6178
  • [Journal-full-title] Connecticut medicine
  • [ISO-abbreviation] Conn Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


41. Katz TS, Amdur RJ, Yachnis AT, Mendenhall WM, Morris CG: Pushing the limits of radiotherapy for atypical and malignant meningioma. Am J Clin Oncol; 2005 Feb;28(1):70-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pushing the limits of radiotherapy for atypical and malignant meningioma.
  • PURPOSE: The purpose of this study was to report the outcome of an extremely aggressive radiotherapy program in patients with atypical and malignant meningioma (60 Gy at 1.5 Gy per fraction twice daily +/- radiosurgery boost).
  • METHODS AND MATERIALS: Thirty-six patients received radiotherapy with curative intent between 1984 and 1999 for atypical (27 patients) or malignant (9 patients) meningioma.
  • CONCLUSION: Our data suggests that 50 to 60 Gy delivered with conventional, once-daily fractionation is probably the optimal schedule for atypical and malignant meningioma.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15685038.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Tummalapalli P, Gondi CS, Dinh DH, Gujrati M, Rao JS: RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis. Int J Oncol; 2007 Jul;31(1):5-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis.
  • Meningiomas are the most commonly occurring tumors of the central nervous system including the brain and spinal cord.
  • Malignant meningiomas are highly aggressive and frequently recur after surgical resection of the tumor.
  • In the present study, we have attempted to evaluate the roles of these molecules in the malignant meningioma tumor microenvironment and to determine the effectiveness of using single or bicistronic small interfering RNA constructs for uPAR and MMP-9 on tumor cell proliferation, migration, invasion, angiogenesis and regression of pre-established orthotopic tumors.
  • Transfection of single or bicistronic constructs downregulated uPAR and MMP-9 in meningioma cells compared to controls.
  • A significant reduction in tumor invasion was determined with matrigel gel and spheroid invasion assays in meningioma cells after transfection of these plasmids.
  • In addition, the present study indicated that targeting both the proteins simultaneously augmented the therapeutic treatment of human meningiomas.

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12493-8 [16891410.001]
  • [Cites] Clin Exp Metastasis. 2005;22(8):643-52 [16649073.001]
  • [Cites] Oncogene. 2002 Apr 11;21(16):2513-24 [11971186.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):289-94 [12527924.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):619-26 [12547719.001]
  • [Cites] Thromb Haemost. 2003 May;89(5):904-14 [12719789.001]
  • [Cites] J Neurosci Methods. 2003 May 30;125(1-2):147-57 [12763241.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):374-84 [12865932.001]
  • [Cites] Acta Neurochir (Wien). 2003 Sep;145(9):777-81; discussion 781 [14505105.001]
  • [Cites] Histol Histopathol. 2004 Jan;19(1):105-12 [14702177.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):201-7 [15069682.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3474-80 [14990990.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4681-9 [15122332.001]
  • [Cites] Science. 2004 Aug 27;305(5688):1289-92 [15297624.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6553-60 [1384965.001]
  • [Cites] Hum Pathol. 1994 Sep;25(9):857-62 [8088759.001]
  • [Cites] Clin Exp Metastasis. 1996 Jan;14(1):12-8 [8521611.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):806-11 [9486653.001]
  • [Cites] Clin Cancer Res. 1999 Jan;5(1):149-53 [9918213.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):173-8 [15538359.001]
  • [Cites] Int J Cancer. 2005 Mar 10;114(1):19-31 [15523695.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2198-205 [15494432.001]
  • [Cites] J Invest Dermatol. 2005 Apr;124(4):839-48 [15816844.001]
  • [Cites] J Biol Chem. 2005 Apr 29;280(17):17449-57 [15728176.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4261-72 [15899818.001]
  • [Cites] EMBO J. 2005 May 18;24(10):1787-97 [15889147.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4074-82 [15930342.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):21882-92 [15824107.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5390-5 [16061852.001]
  • [Cites] Clin Exp Metastasis. 2005;22(4):285-95 [16170665.001]
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1399-408 [16170032.001]
  • [Cites] Biochim Biophys Acta. 2005 Oct 15;1731(1):32-40 [16153722.001]
  • [Cites] J Biol Chem. 2005 Oct 28;280(43):36529-40 [16127174.001]
  • [Cites] Biomaterials. 2006 Mar;27(8):1608-16 [16183114.001]
  • [Cites] Int J Oncol. 2006 Feb;28(2):369-74 [16391791.001]
  • [Cites] Cell Signal. 2006 May;18(5):729-39 [16098714.001]
  • [Cites] Oncol Rep. 2006 Mar;15(3):709-14 [16465434.001]
  • [Cites] Int J Oncol. 2006 Apr;28(4):807-14 [16525628.001]
  • [Cites] Int J Oncol. 2006 Apr;28(4):831-9 [16525631.001]
  • [Cites] Shanghai Kou Qiang Yi Xue. 2006 Feb;15(1):85-7 [16525618.001]
  • [Cites] Neoplasia. 2006 Feb;8(2):96-103 [16611402.001]
  • [Cites] PLoS Med. 2006 Apr;3(4):e96 [16464133.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):35-43 [16680570.001]
  • [Cites] Int J Oncol. 2006 Jun;28(6):1353-60 [16685436.001]
  • [Cites] Hepatology. 2006 Sep;44(3):540-9 [16941692.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):135-42 [16598420.001]
  • [Cites] Methods Mol Biol. 2006;342:33-47 [16957365.001]
  • [Cites] BMC Cancer. 2006;6:211 [16916471.001]
  • [Cites] Prostate. 2006 Nov 1;66(15):1631-40 [16927303.001]
  • [Cites] Peptides. 2006 Dec;27(12):3479-88 [16996648.001]
  • [Cites] J Cell Biochem. 2007 Jan 1;100(1):100-11 [16823770.001]
  • [Cites] Exp Mol Med. 2004 Feb 29;36(1):57-64 [15031672.001]
  • [Cites] J Surg Oncol. 2000 Feb;73(2):95-9 [10694645.001]
  • [Cites] Cell Signal. 2001 May;13(5):363-8 [11369518.001]
  • [Cites] Nature. 2001 May 24;411(6836):494-8 [11373684.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 2001 May;102(5):376-80 [11393999.001]
  • [Cites] Eur J Cancer. 2001 Aug;37(12):1482-7 [11506954.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):971-82 [11549590.001]
  • [Cites] J Biol Chem. 2001 Dec 14;276(50):47171-7 [11572856.001]
  • [Cites] Int J Oncol. 2006 Jun;28(6):1463-70 [16685447.001]
  • [Cites] Mol Cancer Res. 2006 May;4(5):293-302 [16687484.001]
  • [Cites] J Thromb Haemost. 2006 May;4(5):1095-106 [16689764.001]
  • [Cites] Exp Lung Res. 2006 Mar-Apr;32(3-4):69-79 [16754473.001]
  • [Cites] World J Gastroenterol. 2006 Jul 7;12(25):3970-6 [16810742.001]
  • [Cites] Am J Pathol. 2006 Aug;169(2):643-54 [16877362.001]
  • [Cites] J Surg Oncol. 2006 Sep 1;94(3):242-7 [16900513.001]
  • (PMID = 17549400.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS047699-03; United States / NINDS NIH HHS / NS / NS47699; United States / NCI NIH HHS / CA / R01 CA075557-09; United States / NINDS NIH HHS / NS / R01 NS057529; United States / NCI NIH HHS / CA / R01 CA116708-02; United States / NCI NIH HHS / CA / R01 CA075557; United States / NCI NIH HHS / CA / R01 CA095058-04; United States / NCI NIH HHS / CA / CA 75557; United States / NCI NIH HHS / CA / CA116708-02; United States / NCI NIH HHS / CA / CA 92393; United States / NINDS NIH HHS / NS / NS057529-01; United States / NCI NIH HHS / CA / CA 95058; United States / NINDS NIH HHS / NS / R01 NS057529-01; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NINDS NIH HHS / NS / NS057529; United States / NCI NIH HHS / CA / CA092393-04; United States / NCI NIH HHS / CA / R01 CA095058; United States / NINDS NIH HHS / NS / R01 NS047699-03; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA 116708; United States / NCI NIH HHS / CA / R01 CA092393-04; United States / NCI NIH HHS / CA / CA095058-04; United States / NCI NIH HHS / CA / CA075557-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Matrix Metalloproteinase Inhibitors; 0 / PLAUR protein, human; 0 / Plaur protein, mouse; 0 / RNA, Small Interfering; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ NIHMS23454; NLM/ PMC1937039
  •  go-up   go-down


43. Brecknell JE, McLean CA, Hirano H, Malham GM: Disseminated intravascular coagulation complicating resection of a malignant meningioma. Br J Neurosurg; 2006 Aug;20(4):239-41
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated intravascular coagulation complicating resection of a malignant meningioma.
  • A 70-year-old woman developed disseminated intravascular coagulation (DIC) during a craniotomy for a parasagittal anaplastic/malignant meningioma.
  • The tumour was demonstrated to express tissue factor, an important causative factor in other tumour associated DIC and previously shown to be expressed by malignant meningiomas.
  • [MeSH-major] Brain Neoplasms / surgery. Disseminated Intravascular Coagulation / etiology. Intraoperative Complications / etiology. Meningioma / surgery. Neoplasm Proteins / metabolism. Thromboplastin / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954076.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 9035-58-9 / Thromboplastin
  •  go-up   go-down


44. Tamura Y, Miyatake S, Nonoguchi N, Miyata S, Yokoyama K, Doi A, Kuroiwa T, Asada M, Tanabe H, Ono K: Boron neutron capture therapy for recurrent malignant meningioma. Case report. J Neurosurg; 2006 Dec;105(6):898-903
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron neutron capture therapy for recurrent malignant meningioma. Case report.
  • Malignant meningioma is a rare brain tumor with a high risk of recurrence.
  • The authors report the first case of recurrent malignant meningioma treated using boron neutron capture therapy (BNCT).
  • A second resection and three Gamma Knife surgeries could not control progression of the enhancing mass; therefore, the authors applied BNCT based on their experience with it in the treatment of malignant gliomas.
  • The treatment of recurrent malignant meningioma is difficult and has been discouraging thus far.
  • [MeSH-major] Boron Neutron Capture Therapy. Cranial Irradiation. Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Pregnancy Complications, Neoplastic / radiotherapy

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405262.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Tummalapalli P, Spomar D, Gondi CS, Olivero WC, Gujrati M, Dinh DH, Rao JS: RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. Int J Oncol; 2007 Nov;31(5):1039-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis.
  • Malignant meningiomas are highly aggressive and frequently recur after surgical resection of the tumor.
  • In the present study, we made an attempt to evaluate the roles of these proteases in the malignant meningioma tumor microenvironment and determined the effectiveness of using single or bicistronic siRNA constructs for cathepsin B and MMP-9, in both in vitro and in vivo models.
  • The migration and invasion of meningioma cells were decreased after treatment with single or bicistronic siRNA constructs for cathepsin B and MMP-9 compared to controls and vector controls.
  • Our study revealed that abrogation of cathepsin B and MMP-9 expression decreased the activation of major proteins involved in MAP kinase and PI3 kinase pathways indicating that targeting these proteases may hinder intracellular signaling and thus decrease cell survival and proliferation in malignant meningiomas.
  • Furthermore, these observations demonstrate that the simultaneous RNAi-mediated targeting of cathepsin B and MMP-9 has potential application for the treatment of human meningiomas.

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2006 Mar 1;20(5):543-56 [16481467.001]
  • [Cites] Int J Oncol. 2006 Mar;28(3):633-9 [16465367.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):716-28 [16469948.001]
  • [Cites] Oncol Rep. 2006 May;15(5):1321-6 [16596205.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2B):1589-94 [16619576.001]
  • [Cites] Exp Lung Res. 2006 Mar-Apr;32(3-4):69-79 [16754473.001]
  • [Cites] Bull Mem Acad R Med Belg. 2005;160(10-12):417-24; discussion 424-5 [16768246.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6699-707 [16818644.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 1;347(3):566-73 [16843436.001]
  • [Cites] Transplantation. 2006 Aug 15;82(3):340-7 [16906031.001]
  • [Cites] J Clin Invest. 2006 Aug;116(8):2132-2141 [16862213.001]
  • [Cites] Curr Med Chem. 2006;13(19):2309-27 [16918357.001]
  • [Cites] BMC Cancer. 2006;6:211 [16916471.001]
  • [Cites] Neurochem Res. 2006 Sep;31(9):1163-70 [16944316.001]
  • [Cites] Prostate. 2006 Nov 1;66(15):1631-40 [16927303.001]
  • [Cites] Mol Cell Biochem. 2006 Nov;292(1-2):189-95 [16733801.001]
  • [Cites] Gynecol Obstet Invest. 2006;62(4):229-35 [16837781.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;102(1):19-30 [16897429.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 7;1477(1-2):98-111 [10708852.001]
  • [Cites] Cancer. 2001 Mar 1;91(5):972-82 [11251949.001]
  • [Cites] Oncogene. 2001 Jun 21;20(28):3665-73 [11439329.001]
  • [Cites] Oncogene. 2001 Dec 6;20(56):8066-74 [11781819.001]
  • [Cites] Oncogene. 2002 Aug 15;21(36):5601-8 [12165859.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2894-901 [12231534.001]
  • [Cites] Biochem J. 2002 Oct 1;367(Pt 1):209-17 [12086583.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6318-22 [12414663.001]
  • [Cites] Chest. 2003 Feb;123(2):463-7 [12576367.001]
  • [Cites] Biol Chem. 2003 Mar;384(3):447-55 [12715895.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):271-86 [12785001.001]
  • [Cites] J Neurosci. 2003 Jun 15;23(12):4967-74 [12832519.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):316-23 [12845667.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):2767-72 [12926111.001]
  • [Cites] Acta Neurochir (Wien). 2003 Sep;145(9):777-81; discussion 781 [14505105.001]
  • [Cites] Eur Urol. 2003 Nov;44(5):560-6 [14572755.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):27-30 [14729603.001]
  • [Cites] Neoplasma. 2004;51(1):38-43 [15004658.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4681-9 [15122332.001]
  • [Cites] FASEB J. 2004 Jul;18(10):1123-5 [15132991.001]
  • [Cites] J Biol Chem. 2004 Jul 9;279(28):28880-8 [15128735.001]
  • [Cites] Cancer Res. 1991 Feb 15;51(4):1137-42 [1997157.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6553-60 [1384965.001]
  • [Cites] Anat Rec. 1993 Feb;235(2):233-40 [7678371.001]
  • [Cites] Biochim Biophys Acta. 1993 Jul 28;1178(1):55-62 [8329457.001]
  • [Cites] J Cell Sci. 1994 Feb;107 ( Pt 2):373-84 [8207069.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6027-31 [7954439.001]
  • [Cites] Clin Exp Metastasis. 1995 Jan;13(1):49-56 [7820956.001]
  • [Cites] Auris Nasus Larynx. 1995;22(1):43-8 [7677635.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5279-84 [8912869.001]
  • [Cites] Biol Chem. 1996 Nov;377(11):695-702 [8960370.001]
  • [Cites] Matrix Biol. 1998 Mar;16(9):575-84 [9569125.001]
  • [Cites] Hum Pathol. 1998 May;29(5):522-6 [9596278.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12410-5 [9770500.001]
  • [Cites] APMIS. 1999 Jan;107(1):28-37 [10190277.001]
  • [Cites] J Cell Physiol. 1999 Aug;180(2):271-84 [10395297.001]
  • [Cites] Clin Exp Metastasis. 1999 Mar;17(2):177-81 [10411111.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122(6):926-30 [15539385.001]
  • [Cites] Semin Cancer Biol. 2005 Apr;15(2):149-57 [15652460.001]
  • [Cites] Oncology. 2004;67(5-6):450-9 [15714002.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):287-97 [15781315.001]
  • [Cites] Cancer Lett. 2005 Jun 8;223(2):313-22 [15896466.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5158-66 [16033831.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):179-81 [16193389.001]
  • [Cites] Braz J Med Biol Res. 2005 Dec;38(12):1749-57 [16302089.001]
  • [Cites] Histol Histopathol. 2006 Jun;21(6):603-8 [16528670.001]
  • (PMID = 17912429.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS 057529; United States / NINDS NIH HHS / NS / NS047699-03; United States / NCI NIH HHS / CA / R01 CA075557-09; United States / NINDS NIH HHS / NS / R01 NS057529; United States / NCI NIH HHS / CA / CA 95088; United States / NINDS NIH HHS / NS / NS 47699; United States / NCI NIH HHS / CA / R01 CA116708-02; United States / NCI NIH HHS / CA / R01 CA075557; United States / NCI NIH HHS / CA / R01 CA095058-04; United States / NCI NIH HHS / CA / CA 75557; United States / NCI NIH HHS / CA / CA116708-02; United States / NCI NIH HHS / CA / CA 92393; United States / NINDS NIH HHS / NS / NS057529-01; United States / NINDS NIH HHS / NS / R01 NS057529-01; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / CA092393-04; United States / NCI NIH HHS / CA / R01 CA095058; United States / NINDS NIH HHS / NS / R01 NS047699-03; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA 116708; United States / NCI NIH HHS / CA / R01 CA092393-04; United States / NCI NIH HHS / CA / CA095058-04; United States / NCI NIH HHS / CA / CA075557-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.4.22.1 / Cathepsin B; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ NIHMS30797; NLM/ PMC2031211
  •  go-up   go-down


46. Chuang HC, Lee HC, Cho DY: Intracranial malignant meningioma with multiple spinal metastases--a case report and literature review: case report. Spine (Phila Pa 1976); 2006 Dec 15;31(26):E1006-10
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial malignant meningioma with multiple spinal metastases--a case report and literature review: case report.
  • OBJECTIVE: To report a case and review the literature on intracranial malignant meningioma with metastasis to the spine.
  • Pathologic findings indicated malignant meningioma due to bone destruction and dura invasion grossly, and tumor cellular atypism with mitotic activity and massive tumor necrosis microscopically.
  • RESULTS: Both pathologic and immunohistochemical survey found evidence consistent with malignant meningioma with spinal metastasis.
  • Immunohistochemical study has an important role in the differential diagnosis of primary or metastatic intracranial neoplasms.
  • [MeSH-major] Brain Neoplasms / diagnosis. Meningioma / diagnosis. Spinal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningioma, spinal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17172988.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


47. Regel JP, Schoch B, Sandalcioglu IE, Wieland R, Westermeier C, Stolke D, Wiedemayer H: Malignant meningioma as a second malignancy after therapy for acute lymphatic leukemia without cranial radiation. Childs Nerv Syst; 2006 Feb;22(2):172-5
MedlinePlus Health Information. consumer health - Drug Reactions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant meningioma as a second malignancy after therapy for acute lymphatic leukemia without cranial radiation.
  • RATIONALE: Meningiomas in the pediatric age group are very rare tumors, comprising about 1-4.2% of all primary pediatric intracranial tumors.
  • CASE REPORT: We present a 17-year-old patient who suffered from an intraventricular malignant meningioma.
  • In December 2001, 13 years after diagnosis of cALL, he complained of headache, vomiting, and walking difficulties.
  • Histological diagnosis revealed a malignant papillary meningioma.
  • After removal of a recurrent meningioma 16 months later, he received local radiotherapy.
  • CONCLUSION: Pathogenetic mechanisms, treatment options, and prognosis of meningiomas and secondary malignancies of this age group are discussed.
  • [MeSH-major] Drug-Related Side Effects and Adverse Reactions. Meningeal Neoplasms / etiology. Meningioma / etiology. Neoplasms, Second Primary / etiology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Dec 15;95(12):2562-70 [12467071.001]
  • [Cites] Pediatr Neurosurg. 2001 May;34(5):264-7 [11423779.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Neurol Med Chir (Tokyo). 1996 Aug;36(8):598-601 [8831206.001]
  • [Cites] Childs Nerv Syst. 2000 Jul;16(7):406-16 [10958549.001]
  • [Cites] Childs Nerv Syst. 2001 Nov;17 (11):656-62 [11734983.001]
  • [Cites] Med Phys. 2001 Nov;28(11):2387-8 [11764047.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4257-64 [12036851.001]
  • [Cites] Prog Exp Tumor Res. 1987;30:247-54 [3628810.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):964-9 [11420471.001]
  • (PMID = 16456690.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


48. Chen F, Zhang S: Diagnosis and treatment of the primary malignant meningioma in mediastinum: a case report. South Med J; 2009 Nov;102(11):1164-6
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of the primary malignant meningioma in mediastinum: a case report.
  • Primary ectopic meningioma is rare and usually limited to the head and neck region.
  • Until now its occurrence in the mediastinum has not been reported in the literature searched on Medline using the keywords meningioma and mediastinum.
  • We report here a case of primary mediastinal malignant meningioma which was treated by surgical resection and additionally followed by radiotherapy.
  • The clinical features, treatment, pathological findings, and prognosis are analyzed and the literature based on ectopic meningioma is reviewed.
  • [MeSH-major] Mediastinal Neoplasms / diagnosis. Meningioma / diagnosis. Meningioma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19864997.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 6
  •  go-up   go-down


49. Hu W, Shen F, Chen G, Shen G, Liu W, Zhou J: Possible involvement of brain tumour stem cells in the emergence of a fast-growing malignant meningioma after surgical resection and radiotherapy of high-grade astrocytoma: case report and preliminary laboratory investigation. J Int Med Res; 2009 Jan-Feb;37(1):240-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible involvement of brain tumour stem cells in the emergence of a fast-growing malignant meningioma after surgical resection and radiotherapy of high-grade astrocytoma: case report and preliminary laboratory investigation.
  • The case of a 62-year old man diagnosed with radiation-induced meningioma (RIM) after treatment for astrocytoma with an unusually short latency period of 7 months is reported.
  • The patient's clinical condition deteriorated and a second craniotomy was performed with complete removal of the secondary tumour, which was shown to be a malignant meningioma.
  • [MeSH-major] Astrocytoma / radiotherapy. Astrocytoma / surgery. Brain Neoplasms / pathology. Brain Neoplasms / secondary. Meningioma / pathology. Meningioma / secondary. Neoplastic Stem Cells / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215696.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


50. Morina A, Kelmendi F, Morina O, Pazanin L, Dragusha S, Ahmeti F, Morina D: Rhabdoid meningioma in an eight-year-old child. Med Arh; 2010;64(2):123-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdoid meningioma in an eight-year-old child.
  • INTRODUCTION: We report a case of Rhabdoid meningioma in an eight-year-old child which is the fifth case in the world according to our knowledge.
  • The histopathological diagnosis was rhabdoid meningioma (grade III).
  • DISCUSSION: Radical surgery (Simpson grade 1) has been shown to significantly enhance prognosis in atypical and malignant meningiomas.
  • CONCLUSION: Rhabdoid meningioma is an anaplastic, very rare subtype of malignant meningioma.
  • The prognosis for rhabdoid meningioma depends on their proliferative activity and the possibility of radical removal.
  • [MeSH-major] Meningeal Neoplasms. Meningioma. Rhabdoid Tumor

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514784.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


51. Kumar R, Kamdar D, Madden L, Hills C, Crooks D, O'Brien D, Greenman J: Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol Rep; 2006 Jun;15(6):1513-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients.
  • Patients were divided into various groups depending on their histological diagnosis: meningioma (n=11), anaplastic astrocytoma (n=4) and glioblastoma multiforme (GBM; n=46).
  • Significant reduction in serum IL-12 was seen in all groups as compared with the controls: meningioma, p=0.03; anaplastic astrocytoma, p<0.001; and GBM, p<0.001.
  • Conversely, serum IL-10 was significantly increased in anaplastic astrocytoma, p=0.02, and GBM, p=0.03.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology. Glioblastoma / immunology. Interleukin-10 / blood. Interleukin-12 / blood. Meningioma / immunology. Th1 Cells / immunology. Th2 Cells / immunology


52. Kondraganti S, Gondi CS, Gujrati M, McCutcheon I, Dinh DH, Rao JS, Olivero WC: Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line. Int J Oncol; 2006 Jul;29(1):25-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line.
  • Previous studies have shown high expression of TFPI-2 by benign tumors and low or absent expression in highly malignant tumors.
  • Malignant meningiomas constitute 10-15% of all meningiomas and our previous studies revealed loss of expression of TFPI-2 in malignant gliomas.
  • To investigate the role of TFPI-2 in the invasiveness of malignant meningiomas, we stably transfected the human meningioma cell line, IOMM-Lee, with a vector capable of expressing a transcript complementary to the full length of TFPI-2 mRNA in a sense orientation.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Biochem Biophys. 1995 Feb 20;317(1):311-4 [7872799.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4143-7 [8395977.001]
  • [Cites] J Biochem. 1994 Nov;116(5):939-42 [7896752.001]
  • [Cites] Arch Biochem Biophys. 1995 May 10;319(1):55-62 [7539605.001]
  • [Cites] Eur J Biochem. 1996 Jan 15;235(1-2):310-6 [8631347.001]
  • [Cites] Cancer. 1996 May 1;77(9):1877-83 [8646688.001]
  • [Cites] Genomics. 1996 Jul 1;35(1):267-8 [8661135.001]
  • [Cites] Oncology (Williston Park). 1996 May;10(5):747-56; discussion 756-9 [8738830.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1132-6 [9027315.001]
  • [Cites] Cell. 1997 Feb 7;88(3):355-65 [9039262.001]
  • [Cites] Clin Exp Metastasis. 1997 Jul;15(4):440-6 [9219733.001]
  • [Cites] Trends Biochem Sci. 1997 Aug;22(8):299-306 [9270303.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Jan;18(1):40-6 [9445254.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2698-703 [9531578.001]
  • [Cites] Placenta. 1998 Mar-Apr;19(2-3):217-23 [9548189.001]
  • [Cites] Int J Cancer. 1998 May 29;76(5):749-56 [9610735.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9064-6 [9689032.001]
  • [Cites] Semin Thromb Hemost. 1998;24(3):207-10 [9701449.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4461-7 [9766679.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3247-59 [9916987.001]
  • [Cites] Cell Death Differ. 1999 Jul;6(7):673-82 [10453078.001]
  • [Cites] Arch Biochem Biophys. 1999 Oct 1;370(1):112-8 [10496984.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):17-27 [7815129.001]
  • [Cites] J Invest Dermatol. 1995 Mar;104(3):379-83 [7861006.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3353-7 [8159751.001]
  • [Cites] Int J Oncol. 2001 Jan;18(1):127-31 [11115549.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):570-6 [11297250.001]
  • [Cites] J Biol Chem. 2001 Apr 13;276(15):12241-8 [11278667.001]
  • [Cites] Clin Exp Metastasis. 2000;18(3):239-44 [11315097.001]
  • [Cites] Int J Oncol. 2001 Sep;19(3):591-7 [11494041.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):325-33 [11606093.001]
  • [Cites] Oncogene. 2001 Oct 18;20(47):6938-45 [11687973.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2184-91 [11929842.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7758-64 [2253219.001]
  • [Cites] J Biochem. 1990 Oct;108(4):537-43 [1963430.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):5046-53 [1387587.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11832-6 [1465406.001]
  • (PMID = 16773181.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS47699; United States / NCI NIH HHS / CA / R01 CA075557; United States / NCI NIH HHS / CA / CA75557; United States / NCI NIH HHS / CA / CA116708; United States / NCI NIH HHS / CA / CA95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA92393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Glycoproteins; 0 / Laminin; 0 / Lipoproteins; 0 / Proteoglycans; 0 / bcl-2-Associated X Protein; 0 / lipoprotein-associated coagulation inhibitor; 0 / tissue-factor-pathway inhibitor 2; 119978-18-6 / matrigel; 9007-34-5 / Collagen; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ NIHMS9141; NLM/ PMC1479607
  •  go-up   go-down


53. Goutagny S, Yang HW, Zucman-Rossi J, Chan J, Dreyfuss JM, Park PJ, Black PM, Giovannini M, Carroll RS, Kalamarides M: Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res; 2010 Aug 15;16(16):4155-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status.
  • PURPOSE: Meningiomas are the most common central nervous system tumors in the population of age 35 and older.
  • Clinical data supporting histologic malignant progression of meningiomas are sparse and underlying molecular mechanisms are not clearly depicted.
  • EXPERIMENTAL DESIGN: We identified genetic alterations associated with histologic progression of 36 paired meningioma samples in 18 patients using 500K SNP genotyping arrays and NF2 gene sequencing.
  • RESULTS: The most frequent chromosome alterations observed in progressing meningioma samples are early alterations (i.e., present both in lower- and higher-grade samples of a single patient).
  • In our series, NF2 gene inactivation was an early and frequent event in progressing meningioma samples (73%).
  • Chromosome alterations acquired during progression from grade I to grade II meningioma were not recurrent.
  • CONCLUSION: Meningiomas displayed different patterns of genetic alterations during progression according to their NF2 status: NF2-mutated meningiomas showed higher chromosome instability during progression than NF2-nonmutated meningiomas, which had very few imbalanced chromosome segments.
  • This pattern of alterations could thus be used as markers in clinical practice to identify tumors prone to progress among grade I meningiomas.
  • [MeSH-major] Genes, Neurofibromatosis 2. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20682713.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Avninder S, Vermani S, Shruti S, Chand K: Papillary meningioma: a rare but distinct variant of malignant meningioma. Diagn Pathol; 2007;2:3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary meningioma: a rare but distinct variant of malignant meningioma.
  • BACKGROUND: Papillary meningiomas are rare meningeal tumors and are associated with aggressive clinical behavior as compared with other meningiomas.
  • We report a case of papillary meningioma in a 16-year-old boy.
  • MRI revealed a large bifrontal meningioma which showed presence of a predominantly papillary pattern with areas of focal necrosis, frequent mitoses and bone invasion.
  • CONCLUSION: Papillary meningiomas are rare but well recognized variants of meningioma.
  • They are malignant, frequently show bone and parenchymatous invasion and have the potential for extracranial metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurol Scand. 2000 Sep;102(3):200-2 [10987382.001]
  • [Cites] Surg Neurol. 2001 Jul;56(1):8-20; discussion 20-1 [11546562.001]
  • [Cites] Cancer. 1975 Oct;36(4):1363-73 [1175134.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Oct;28(5):418-21 [12366823.001]
  • [Cites] Brain Tumor Pathol. 2004;21(3):143-7 [15696976.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] J Neurosurg. 1986 May;64(5):808-12 [3701427.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):299-305 [3719522.001]
  • [Cites] Indian J Cancer. 1993 Dec;30(4):164-8 [8206498.001]
  • [Cites] Pediatr Radiol. 1995 Nov;25 Suppl 1:S9-13 [8577564.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):478-82 [2915253.001]
  • (PMID = 17233924.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1796851
  •  go-up   go-down


55. Gupta V, Su YS, Samuelson CG, Liebes LF, Chamberlain MC, Hofman FM, Schönthal AH, Chen TC: Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. J Neurosurg; 2007 Mar;106(3):455-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas.
  • OBJECT: There is currently no effective chemotherapy for meningiomas.
  • Although most meningiomas are treated surgically, atypical or malignant meningiomas and surgically inaccessible meningiomas may not be removed completely.
  • The authors have investigated the effects of the topoisomerase I inhibitor irinotecan (CPT-11) on primary meningioma cultures and a malignant meningioma cell line in vitro and in vivo.
  • METHODS: The effects of irinotecan on cellular proliferation in primary meningioma cultures and the IOMM-Lee malignant meningioma cell line were measured by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium bromide assay and flow cytometry.
  • The effects of irinotecan in vivo on a meningioma model were determined with a subcutaneous murine tumor model using the IOMM-Lee cell line.
  • Irinotecan induced a dose-dependent antiproliferative effect with subsequent apoptosis in the primary meningioma cultures (at doses up to 100 microM) as well as in the IOMM-Lee human malignant meningioma cell line (at doses up to 20 microM) irinotecan.
  • CONCLUSIONS: Irinotecan demonstrated growth-inhibitory effects in meningiomas both in vitro and in vivo.
  • Irinotecan was much more effective against the malignant meningioma cell line than against primary meningioma cultures.
  • Therefore, this drug may have an important therapeutic role in the treatment of atypical or malignant meningiomas and should be evaluated further for this purpose.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Meningioma / drug therapy. Meningioma / pathology. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / pathology. Subcutaneous Tissue

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367069.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Proto-Oncogene Proteins c-bcl-2; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


56. Shivane AG, Chakrabarty A, Baborie A, Thiryayi W, Donaldson MH, Ross S: A rare case of recurrent secretory meningioma with malignant transformation. Br J Neurosurg; 2006 Aug;20(4):250-3
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of recurrent secretory meningioma with malignant transformation.
  • A 72-year-old woman previously operated for a sphenoid-ridge meningioma, now presented with double vision.
  • Histology showed a secretory meningioma with an epithelial-appearing, malignant component.
  • Malignant transformation in a secretory meningioma is not known.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neoplasm Recurrence, Local / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954080.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Martínez-Lage JF, Ferri Niguez B, Sola J, Pérez-Espejo MA, Ros de San Pedro J, Fernandez-Cornejo V: Rhabdoid meningioma: a new subtype of malignant meningioma also apt to occur in children. Childs Nerv Syst; 2006 Mar;22(3):325-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdoid meningioma: a new subtype of malignant meningioma also apt to occur in children.
  • A left frontal extra-axial tumor was totally removed, whose histopathologic diagnosis was rhabdoid meningioma (RM).
  • DISCUSSION: Rhabdoid meningiomas constitute a special malignant phenotype of meningioma that has been recently included in the WHO classification of tumors of the nervous system.
  • We report the fourth case of a RM occurring in a child to illustrate that the diagnosis of this tumor subtype, given its prognostic implications, must also be considered in pediatric patients.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Rhabdoid Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 2003 Nov;29(5):292-6 [14595799.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 2000 Jun;63(6):492-7 [10925541.001]
  • [Cites] Orv Hetil. 2000 May 7;141(19):1025-30 [10846425.001]
  • [Cites] Pathologe. 2002 Jul;23 (4):297-302 [12185783.001]
  • [Cites] Brain Pathol. 2001 Oct;11(4):481-2, 487 [11556694.001]
  • [Cites] J Neuroimmunol. 2001 Nov 1;120(1-2):129-37 [11694327.001]
  • [Cites] Diagn Cytopathol. 2003 Nov;29(5):297-9 [14595800.001]
  • [Cites] Arq Neuropsiquiatr. 2003 Jun;61(2A):277-80 [12806512.001]
  • [Cites] Clin Neuropathol. 2004 Jan-Feb;23(1):16-20 [14986929.001]
  • [Cites] Singapore Med J. 2000 Sep;41(9):464-7 [11193122.001]
  • [Cites] Brain Tumor Pathol. 2001;18(2):155-9 [11908873.001]
  • [Cites] J Neurosurg. 2002 Dec;97(6):1450-5 [12507148.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):231-8 [9500225.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1482-90 [9850174.001]
  • [Cites] J Neurosurg. 1994 Mar;80(3):447-53 [8113857.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):964-9 [11420471.001]
  • (PMID = 15800791.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


58. Colen CB, Rayes M, Kupsky WJ, Guthikonda M: Synchronous meningioma and anaplastic large cell lymphoma. Neuropathology; 2010 Jun;30(3):260-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous meningioma and anaplastic large cell lymphoma.
  • To the best of our knowledge, we report the first case of an atypical meningioma infiltrated by a T-cell-primary central nervous system lymphoma (PCNSL), specifically anaplastic large cell lymphoma (ALCL).
  • A 65-year-old man with a history of near-total resection of atypical meningioma presented with a complaint of progressive headaches.
  • The remainder of the specimen consisted of densely cellular neoplasm centered in connective tissue, including areas involved by meningioma.
  • These cells were strongly immunoreactive for CD3 and CD30 but remained unstained with EMA, anaplastic lymphoma kinase-1 (ALK-1), CD15 or cytotoxic associated antigen TIA-1.
  • The morphologic and immunohistochemical features were considered typical of anaplastic large T-cell lymphoma.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology


59. Hope AJ, Mansur DB, Tu PH, Simpson JR: Metachronous secondary atypical meningioma and anaplastic astrocytoma after postoperative craniospinal irradiation for medulloblastoma. Childs Nerv Syst; 2006 Sep;22(9):1201-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous secondary atypical meningioma and anaplastic astrocytoma after postoperative craniospinal irradiation for medulloblastoma.
  • INTRODUCTION: Malignant brain tumors have been reported to occur after childhood irradiation more frequently than in the nonirradiated population.
  • DISCUSSION: In this study, we report the case of a 15-year-old boy treated for medulloblastoma with surgery and craniospinal radiotherapy, who developed a meningioma 18 years after initial treatment and subsequently an anaplastic astrocytoma 23 years after primary treatment.
  • The meningioma was resected without complications.
  • [MeSH-major] Astrocytoma / diagnosis. Cerebellar Neoplasms / radiotherapy. Cranial Irradiation / adverse effects. Medulloblastoma / radiotherapy. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1987 Dec;67(6):915-8 [2824720.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3761-7 [9850019.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):469-74 [2536806.001]
  • [Cites] Ann Neurol. 1978 Oct;4(4):319-21 [727737.001]
  • [Cites] Childs Nerv Syst. 2000 Jul;16(7):390-7 [10958546.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):65-73 [10924973.001]
  • [Cites] Childs Nerv Syst. 2004 Apr;20(4):243-6 [14704813.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):426-9 [6581853.001]
  • [Cites] Lancet. 1997 May 10;349(9062):1369 [9149706.001]
  • [Cites] J Pediatr Endocrinol Metab. 2003 Jan;16(1):97-101 [12585346.001]
  • [Cites] Surg Neurol. 2003 Jul;60(1):60-7; discussion 67 [12865017.001]
  • [Cites] Clin Neuropathol. 1994 Sep-Oct;13(5):281-5 [7805312.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] Pediatr Neurosurg. 1996 Oct;25(4):214-9 [9293548.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):111-5 [9420081.001]
  • [Cites] J Neurosurg. 1978 Apr;48(4):622-7 [632887.001]
  • [Cites] BMJ. 1993 Oct 23;307(6911):1030-6 [8251777.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Cancer Causes Control. 1997 Nov;8(6):865-71 [9427429.001]
  • [Cites] Neurosurgery. 1995 Apr;36(4):685-90 [7596497.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(7):697-700 [11534690.001]
  • [Cites] J Neuroradiol. 1983;10 (1):43-9 [6864263.001]
  • [Cites] Neurology. 1981 May;31(5):616-9 [7194977.001]
  • [Cites] Neurosurgery. 1980 May;6(5):546-51 [6251397.001]
  • [Cites] Lancet. 1974 Feb 23;1(7852):277-9 [4130470.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):154-62 [7782835.001]
  • [Cites] Clin Neurol Neurosurg. 1998 Mar;100(1):56-9 [9637208.001]
  • [Cites] Can J Neurol Sci. 1984 Nov;11(4):475-8 [6518432.001]
  • [Cites] Arch Ophthalmol. 1988 Dec;106(12 ):1701-5 [3196211.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):485-91 [10023719.001]
  • [Cites] Onkologie. 2001 Feb;24(1):66-72 [11441284.001]
  • [Cites] Eur J Paediatr Neurol. 1999;3(4):177-80 [10476368.001]
  • [Cites] Can J Neurol Sci. 1992 Nov;19(4):498-503 [1330262.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):445-9 [682008.001]
  • [Cites] Am J Public Health Nations Health. 1966 Dec;56(12):2114-20 [5334312.001]
  • [Cites] Cancer. 1979 Jan;43(1):129-36 [104784.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Oct;23(7):431-6 [11878577.001]
  • (PMID = 16570196.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 40
  •  go-up   go-down


60. Haase D, Schmidl S, Ewald C, Kalff R, Huebner C, Firsching R, Keilhoff G, Evert M, Paulus W, Gutmann DH, Lal A, Mawrin C: Fatty acid synthase as a novel target for meningioma therapy. Neuro Oncol; 2010 Aug;12(8):844-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatty acid synthase as a novel target for meningioma therapy.
  • Similar to other hormone receptor-positive tumor types, meningiomas are progesterone receptor- and estrogen receptor-immunoreactive brain tumors.
  • To define the role of FAS in human meningioma growth control, we first analyzed the FAS expression using a tissue microarray containing 38 meningiomas and showed increased FAS expression in 70% of atypical WHO grade II and anaplastic WHO grade III meningiomas compared with 10% of benign WHO grade I tumors.
  • Second, we demonstrated that treatment with the FAS inhibitor, cerulenin (Cer), significantly decreased meningioma cell survival in vitro.
  • Fourth, we demonstrated that Cer treatment of mice bearing meningioma xenografts resulted in significantly reduced tumor volumes associated with increased meningioma cell death.
  • Collectively, our data suggest that the increased FAS expression in human meningiomas represents a novel therapeutic target for the treatment of unresectable or malignant meningioma.
  • [MeSH-major] Cerulenin / pharmacology. Fatty Acid Synthases / metabolism. Fatty Acid Synthesis Inhibitors / pharmacology. Meningeal Neoplasms / enzymology. Meningioma / enzymology

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 2000 May;48(5):613-22 [10769045.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3450-4 [10716717.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):153-7 [11205903.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1493-9 [11245456.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1626-35 [11920521.001]
  • [Cites] Exp Cell Res. 2003 Jan 15;282(2):132-7 [12531699.001]
  • [Cites] Histopathology. 2003 Sep;43(3):280-90 [12940781.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7794-808 [14560023.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7330-7 [14612531.001]
  • [Cites] Oncol Rep. 2004 Aug;12(2):411-22 [15254710.001]
  • [Cites] Ann Neurol. 2004 Aug;56(2):295-8 [15293284.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36608-15 [15220355.001]
  • [Cites] J Biochem. 1989 May;105(5):751-5 [2666407.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2243-9 [2804914.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6379-83 [8022791.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1189-93 [8640795.001]
  • [Cites] Int J Gynecol Pathol. 1997 Jan;16(1):45-51 [8986532.001]
  • [Cites] Neurology. 1997 Jul;49(1):267-70 [9222206.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4589-93 [9494573.001]
  • [Cites] Am J Physiol. 1999 Aug;277(2 Pt 1):L381-90 [10444533.001]
  • [Cites] Lab Invest. 2005 Jan;85(1):99-108 [15543204.001]
  • [Cites] Oncogene. 2005 Jan 6;24(1):39-46 [15489885.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] J Pathol. 2005 Jun;206(2):214-9 [15880754.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4074-82 [15930342.001]
  • [Cites] Oncogene. 2005 May 19;24(22):3574-82 [15806173.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5070-5 [15958550.001]
  • [Cites] Clin Neuropathol. 2005 Jul-Aug;24(4):175-83 [16033134.001]
  • [Cites] Lab Invest. 2005 Sep;85(9):1163-71 [15965488.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):5977-80 [16778164.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):869-78 [16969344.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):735-45 [17234785.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):763-77 [17882277.001]
  • [Cites] Biomed Pharmacother. 2007 Oct;61(9):578-87 [17904792.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):314-22 [18172325.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • (PMID = 20511185.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acid Synthesis Inhibitors; 0 / RNA, Messenger; 17397-89-6 / Cerulenin; EC 2.3.1.85 / Fatty Acid Synthases
  • [Other-IDs] NLM/ PMC2940685
  •  go-up   go-down


61. Mawrin C, Sasse T, Kirches E, Kropf S, Schneider T, Grimm C, Pambor C, Vorwerk CK, Firsching R, Lendeckel U, Dietzmann K: Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res; 2005 Jun 1;11(11):4074-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.
  • PURPOSE: Activation of intracellular signaling cascades has been implicated in the growth control of benign meningiomas, but their role for meningioma progression and outcome is unknown.
  • Here we determined the expression and function of proteins involved in mitogen-activated protein kinase (MAPK) and phosphinositol-3 kinase (PI3K)/Akt signaling in benign, atypical, and malignant meningiomas and studied their association with clinicopathologic data including meningioma recurrence.
  • EXPERIMENTAL DESIGN: Expression of various MAPK and PI3K signaling proteins was determined in 70 primary meningiomas and, if present, in recurrent tumors by immunohistochemistry and Western blotting.
  • The effect of MAPK and PI3K pathway inhibition on cell proliferation and apoptosis was determined using a primary malignant meningioma cell culture.
  • RESULTS: Atypical and malignant meningiomas showed higher levels of phospho-Akt compared with benign tumors, and their proliferation could be inhibited by PI3K blocking using wortmannin.
  • PI3K inhibition did not induce apoptosis in malignant meningioma cells.
  • In contrast, expression of phospho-Raf and phospho-MAPK was decreased in aggressive meningiomas compared with benign tumors, but MAPK inhibition by PD98059 resulted in tumor cell apoptosis and decreased proliferation.
  • Reduced MAPK activation was associated with meningioma recurrence, and PI3K activation was associated with poor preclinical condition and brain invasion of malignant meningiomas.
  • CONCLUSIONS: Both MAPK and PI3K/Akt pathways are activated at different levels in benign and malignant meningiomas.
  • Activation of PI3K/Akt signaling contributes to the aggressive behavior of malignant meningiomas, whereas MAPK activation is involved in both proliferation and apoptosis of malignant meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Mitogen-Activated Protein Kinases / metabolism. Protein-Serine-Threonine Kinases / metabolism. Proto-Oncogene Proteins / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15930342.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Androstadienes; 0 / Flavonoids; 0 / Ki-67 Antigen; 0 / Platelet-Derived Growth Factor; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / raf Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.1.4.- / Type C Phospholipases; EC 3.1.4.3 / Phospholipase C gamma; EC 3.6.5.2 / ras Proteins; XVA4O219QW / wortmannin
  •  go-up   go-down


62. Tong-tong W, Li-juan B, Zhi L, Yang L, Bo-ning L, Quan H: Clear cell meningioma with anaplastic features: case report and review of literature. Pathol Res Pract; 2010 May 15;206(5):349-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell meningioma with anaplastic features: case report and review of literature.
  • Clear cell meningioma (CCM) is an uncommon variant of meningioma, corresponding to WHO grade II.
  • We present two cases of CCMs with anaplastic features in the intracranial and intraspinal region.
  • On histological examination, both tumors partly exhibited unusual anaplastic appearances with nuclear pleomorphism, high mitotic activity and necrosis, distinct from classical CCMs.
  • A diagnosis of CCM with anaplastic features was made (WHO grade III).
  • [MeSH-major] Frontal Lobe / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009. Published by Elsevier GmbH. All rights reserved.
  • (PMID = 19857933.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Rosenberg LA, Prayson RA, Lee J, Reddy C, Chao ST, Barnett GH, Vogelbaum MA, Suh JH: Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution. Int J Radiat Oncol Biol Phys; 2009 Jun 1;74(2):427-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution.
  • PURPOSE: To evaluate the outcomes for patients with Grade III meningiomas as defined by the 2007 World Health Organization standards.
  • METHODS AND MATERIALS: The slides from patients who had been treated at the Cleveland Clinic for malignant meningiomas were reviewed by a single neuropathologist.
  • The data from 13 patients treated between 1984 and 2006 satisfied the World Health Organization 2007 definition of Grade III meningioma.
  • CONCLUSION: This is one of the few studies reporting the outcomes for malignant meningioma patients according to recent definitions.
  • Our results are consistent with existing reports of the overall poor outcomes for atypical and malignant meningioma patients.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / surgery. Meningioma / radiotherapy. Meningioma / surgery. Salvage Therapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19427553.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Miyatake S, Kawabata S, Nonoguchi N, Yokoyama K, Kuroiwa T, Matsui H, Ono K: Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas. Neuro Oncol; 2009 Aug;11(4):430-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas.
  • Pseudoprogression has been recognized and widely accepted in the treatment of malignant gliomas, as transient increases in the volume of the enhanced area just after chemoradiotherapy, especially using temozolomide.
  • We experienced a similar phenomenon in the treatment of malignant gliomas and meningiomas using boron neutron capture therapy (BNCT), a cell-selective form of particle radiation.
  • Fifty-two cases of malignant glioma and 13 cases of malignant meningioma who were treated by BNCT were reviewed retrospectively mainly via MR images.
  • Eleven of 52 malignant gliomas and 3 of 13 malignant meningiomas showed transient increases of enhanced volume in MR images within 3 months after BNCT.
  • Fluoride-labeled boronophenylalanine PET was applied in four and two cases of malignant gliomas and meningiomas, respectively, at the time of transient increase of lesions.
  • Transient increases in enhanced volume in malignant gliomas and meningiomas immediately after BNCT seemed to be pseudoprogression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5888-95 [14676111.001]
  • [Cites] J Radiat Res. 2009 Jan;50(1):51-60 [18957828.001]
  • [Cites] Neurology. 2004 Aug 10;63(3):535-7 [15304589.001]
  • [Cites] Ann Nucl Med. 2004 Jun;18(4):291-6 [15359921.001]
  • [Cites] Mol Interv. 2004 Oct;4(5):273-84 [15471910.001]
  • [Cites] J Immunol. 1984 Oct;133(4):1710-5 [6206131.001]
  • [Cites] Radiologe. 1986 Apr;26(4):206-9 [3012629.001]
  • [Cites] Acta Oncol. 1990;29(7):891-5 [2261204.001]
  • [Cites] Int J Rad Appl Instrum A. 1991;42(4):325-8 [1850716.001]
  • [Cites] Med Pediatr Oncol. 1991;19(3):182-6 [1902547.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):433-41 [8892469.001]
  • [Cites] J Neurooncol. 1997 May;33(1-2):163-9 [9151233.001]
  • [Cites] Radiat Res. 1998 Feb;149(2):163-70 [9457896.001]
  • [Cites] J Nucl Med. 1998 Feb;39(2):325-33 [9476945.001]
  • [Cites] Clin Cancer Res. 1998 Aug;4(8):1825-32 [9717808.001]
  • [Cites] Clin Cancer Res. 1998 Aug;4(8):1833-41 [9717809.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] J Neurosurg. 2005 Dec;103(6):1000-9 [16381186.001]
  • [Cites] Acta Neuropathol. 2006 Mar;111(3):197-212 [16463065.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Aug;27(7):1432-7 [16908552.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):323-6 [17236958.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):81-3 [16944309.001]
  • [Cites] J Neurosurg. 2006 Dec;105(6):898-903 [17405262.001]
  • [Cites] Neurosurgery. 2007 Jul;61(1):82-90; discussion 90-1 [17621022.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1350-60 [18037587.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2192-7 [18445844.001]
  • [Cites] Lancet Oncol. 2008 May;9(5):453-61 [18452856.001]
  • [Cites] Cancer. 2008 Jul 15;113(2):405-10 [18484594.001]
  • [Cites] J Neurooncol. 2008 Sep;89(2):239-46 [18566749.001]
  • [Cites] J Neurooncol. 2003 Nov;65(2):159-65 [14686736.001]
  • (PMID = 19289492.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2743223
  •  go-up   go-down


65. Maes L, Van Neste L, Van Damme K, Kalala JP, De Ridder L, Bekaert S, Cornelissen M: Relation between telomerase activity, hTERT and telomere length for intracranial tumours. Oncol Rep; 2007 Dec;18(6):1571-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study analysed the telomerase activity, hTERT protein and telomere length in meningiomas and gliomas in relation to their WHO grading.
  • Telomerase activity was detected in 3 of 35 (8.6%) screened meningiomas (1 benign, 1 atypical and 1 malignant meningioma).
  • For hTERT expression, 56.4% of meningiomas were positive with a mean labelling index (hTERT LI) of 31.3% (SD=26.5) for the hTERT positive meningiomas.
  • The mean telomere length for meningiomas was 6.983 kb (SD=1.969).
  • The anaplastic astrocytoma had a telomere length of 4.903 kb and the glioblastomas 5.767 kb (SD=2.042).
  • These results indicate that telomere shortening may be a critical step in pathogenesis of atypical and malignant meningiomas and gliomas.
  • [MeSH-major] Brain Neoplasms / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology. Telomerase / metabolism. Telomere / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17982646.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


66. Liu Y, Pang JC, Dong S, Mao B, Poon WS, Ng HK: Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas. Hum Pathol; 2005 Apr;36(4):416-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas.
  • The aim of this study was to investigate whether promoter hypermethylation of cancer-related genes is involved in the development and progression of meningiomas.
  • The methylation status at the promoter region of 10 cancer-related genes was examined by methylation-specific polymerase chain reaction in a cohort of 48 meningiomas including 16 benign, 19 atypical, and 13 anaplastic variants.
  • Our results showed that 50% (24/48) of meningiomas exhibited promoter hypermethylation in at least one of the genes but not in normal leptomeninges, indicating that aberrant hypermethylation is tumor-specific.
  • Treatment of IOMM-Lee meningioma cell line with 5-aza-2'-deoxycytidine restored expression of O 6 -methylguanine-DNA methyltransferase and death-associated protein kinase 1, providing evidence that promoter hypermethylation contributes to transcriptional silencing.
  • The frequencies of methylation of any single gene in benign, atypical, and malignant meningiomas were 6% (1/16), 74% (14/19), and 69% (9/13), respectively.
  • Of 48 tumors, 13 (27%) showed that concurrent hypermethylation of two or more genes studied were of atypical or anaplastic type.
  • Statistical analysis revealed that the incidence of promoter hypermethylation of any single gene, of multiple genes, or of glutathione S -transferase P1 was significantly associated with atypical and anaplastic meningiomas ( P < .0001, P = .004, and P = .004, respectively).
  • In conclusion, this study demonstrates that aberrant hypermethylation profile is associated with atypical and anaplastic meningiomas, suggesting that epigenetic change may be involved in malignant progression of meningiomas.
  • [MeSH-major] Azacitidine / analogs & derivatives. CpG Islands. DNA Methylation. Meningioma / genetics. Promoter Regions, Genetic

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15892004.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


67. Alexiou GA, Vartholomatos G, Tsiouris S, Papadopoulos A, Kyritsis AP, Polyzoidis KS, Voulgaris S, Fotopoulos AD: Evaluation of meningioma aggressiveness by (99m)Tc-Tetrofosmin SPECT. Clin Neurol Neurosurg; 2008 Jul;110(7):645-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of meningioma aggressiveness by (99m)Tc-Tetrofosmin SPECT.
  • OBJECTIVES: Although meningiomas usually have a benign clinical course, atypical and malignant types of this brain tumor are associated with high recurrence rates and poor outcome; thus, DNA ploidy and S-phase -- as determined by DNA flow cytometry -- are useful indicators of their biological behavior.
  • This study evaluated whether (99m)Tc-Tetrofosmin ((99m)Tc-TF) uptake correlates with meningioma proliferative activity, as assessed by flow cytometry analysis.
  • PATIENTS AND METHODS: Ten consecutive patients (3 males, 7 females, mean age 64.6 years) with a diagnosis of a symptomatic intracranial meningioma, planned to undergo surgery, were studied.
  • RESULTS: Benign meningiomas were diagnosed in 8/10 cases, the remaining 2/10 patients had anaplastic lesions.
  • CONCLUSION: These results imply that (99m)Tc-TF brain SPECT may have the ability to discriminate benign meningiomas from malignant meningiomas pre-operatively, the tracer uptake being a likely indicator of their proliferative activity.
  • [MeSH-major] Meningeal Neoplasms / radionuclide imaging. Meningioma / radionuclide imaging. Organophosphorus Compounds. Organotechnetium Compounds. Tomography, Emission-Computed, Single-Photon / methods

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18471956.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


68. Greene S, Nair N, Ojemann JG, Ellenbogen RG, Avellino AM: Meningiomas in children. Pediatr Neurosurg; 2008;44(1):9-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningiomas in children.
  • OBJECTIVE: Pediatric meningioma is a rare diagnosis.
  • This retrospective review seeks to elucidate pertinent characteristics of pediatric patients presenting with meningioma.
  • Five patients had radiation-induced meningiomas.
  • Ten patients had spontaneously arising meningiomas, 2 of which were malignant.
  • CONCLUSION: Patients with spontaneously arising meningiomas were younger than those with identified risk factors.
  • There was no recurrence in patients with radiation-induced meningiomas.
  • The only death occurred in a patient with a malignant meningioma.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neoplasms, Radiation-Induced / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18097185.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 15
  •  go-up   go-down


69. Ghodsian M, Obrzut SL, Hyde CC, Watts WJ, Schiepers C: Evaluation of metastatic meningioma with 2-deoxy-2-[18F]fluoro-D-glucose PET/CT. Clin Nucl Med; 2005 Nov;30(11):717-20
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of metastatic meningioma with 2-deoxy-2-[18F]fluoro-D-glucose PET/CT.
  • PURPOSE: The purpose of this study was to characterize the 2-deoxy-2-[18F]fluoro-D-glucose (FDG) PET/CT imaging findings of sacral metastatic meningioma.
  • MATERIALS AND METHODS: An 18-year-old woman with a history of metastatic meningioma, who presented with intractable pain and spasm of the right lower extremity, underwent FDG PET/CT imaging.
  • The biopsy of the lesion was consistent with a high-grade malignant meningioma.
  • CONCLUSIONS: Although meningioma is typically a benign tumor, in rare instances, it metastasizes.
  • [MeSH-major] Brain Neoplasms / diagnosis. Fluorodeoxyglucose F18. Meningioma / diagnosis. Meningioma / secondary. Positron-Emission Tomography / methods. Spinal Neoplasms / diagnosis. Spinal Neoplasms / secondary. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Female. Humans. Lower Extremity / radiography. Lower Extremity / radionuclide imaging. Pain / diagnosis. Pain / etiology. Radiopharmaceuticals. Sacrum / radiography. Sacrum / radionuclide imaging. Spasm / diagnosis. Spasm / etiology

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16237292.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


70. Borgmann A, Zinn C, Hartmann R, Herold R, Kaatsch P, Escherich G, Möricke A, Henze G, von Stackelberg A, ALL-REZ BFM Study Group: Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. Eur J Cancer; 2008 Jan;44(2):257-68

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood.
  • PURPOSE: To investigate the cumulative incidence of and the risk factors for developing second malignant neoplasms (SMN) in children and adolescents following treatment for relapse of acute lymphocytic leukaemia (ALL).
  • RESULTS: Out of the 1376 patients 21 were diagnosed with SMN including non-lymphoblastic leukaemia/myelodysplastic syndrome (n=6), osteo-/Ewing's-/fibroblastic sarcoma (n=4), B-cell ALL/lymphoma (n=2), thyroid carcinoma (n=2), basal cell carcinoma, adeno carcinoma, squamous cell carcinoma, meningioma, malignant histiocytosis, glioblastoma and anaplastic astrocytoma (n=1 each).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17981026.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Mertens R; Imbach P; Pongratz E; Rupprecht T; Henze G; Wickmann L; Otte J; Bode U; Eberl W; Pekrun A; Kirschstein M; Hofmann K; Frank R; Möbius D; Andler W; Niekrens C; Breu H; Suttorp M; Göbel U; Weinmann G; Sauerbrey A; Beck JF; Janka-Schaub G; Welte K; Kulozik A; Tautz C; Graf N; Fink FM; Zintl F; Hermann J; Rupprath G; Dupuis W; Rodehüser M; Schrappe M; Berthold F; Sternschulte W; Körholz D; Schmitt K; Selle B; Gutjahr P; Dürken M; Christiansen H; Rose M; Borkhardt A; Burdach S; Jürgens H; Scheurlen W; Eggers G; Geib R; Dickerhoff R; Bielack S; Rauh W; Niethammer D; Debatin KM; Gadner H; Dohrn B; Schlegel PG; Niggli F
  •  go-up   go-down


76. Erman T, Hanta I, Haciyakupoğlu S, Zorludemir S, Zeren H, Göçer AI: Huge bilateral pulmonary and pleural metastasis from intracranial meningioma: a case report and review of the literature. J Neurooncol; 2005 Sep;74(2):179-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huge bilateral pulmonary and pleural metastasis from intracranial meningioma: a case report and review of the literature.
  • A case of recurrent meningioma with atypical features and extracranial metastases is reported.
  • A 34-year-old female was operated in 1996, 2000, and 2002, and frontal parasagittal meningioma was extirpated.
  • Histological diagnoses of all the resected tumors were meningotheliomatous meningioma, WHO Grade I.
  • Histological diagnosis was reported as an atypical meningioma; meningotheliomatous type; WHO Grade II.
  • Cytopathology was consistent with malignant meningioma, metastasis from the patient's known intracranial meningioma.
  • We reviewed and discussed the histopathological features and mechanisms of metastasizing meningioma.
  • [MeSH-major] Lung Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / secondary. Pleural Neoplasms / secondary

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16193389.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


77. Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G, Lichter P: Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer; 2005 Mar 20;114(2):249-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression.
  • To identify gene expression profiles associated with human meningiomas of different World Health Organization (WHO) malignancy grades, we analyzed 30 tumors (13 benign meningiomas, WHO grade I; 12 atypical meningiomas, WHO grade II; 5 anaplastic meningiomas, WHO grade III) for the expression of 2,600 genes using cDNA-microarray technology.
  • Receiver operator curve (ROC) analysis with a cutoff value of 45% selection probability identified 37 genes with decreased and 27 genes with increased expression in atypical and anaplastic meningiomas, compared to benign meningiomas.
  • However, anaplastic meningiomas could be distinguished from benign meningiomas by differential expression of a distinct set of genes, including several ones associated with cell cycle regulation and proliferation.
  • Taken together, our microarray-based expression profiling revealed interesting novel candidate genes and pathways that may contribute to meningioma progression.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Meningeal Neoplasms / genetics. Meningioma / genetics. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15540215.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


78. Ali S, Nassar A, Siddiqui MT: Crush preparations of meningiomas: can grading be accomplished? Diagn Cytopathol; 2008 Nov;36(11):827-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crush preparations of meningiomas: can grading be accomplished?
  • Crush preparations (CP) for the diagnosis of meningioma are routinely performed in the frozen section suite when tissue is submitted for intraoperative consultation.
  • The goal of this study was to examine the cytologic features of meningiomas in CP and evaluate if benign meningioma (Grade 1), atypical meningioma (Grade 2), and malignant meningioma (Grade 3) can be diagnosed on CP.
  • All cases of meningioma (1999-2007), which were submitted for frozen section at our institution, were retrospectively reviewed.
  • The final histologic diagnosis was taken as the gold standard.
  • A total of 107 meningiomas cases were reviewed.
  • Using the final histopathologic diagnosis as the gold standard, there were 72 (Grade 1), 22 (Grade 2), and 13 (Grade 3) meningioma cases, which were studied.
  • In conclusion, this study reviews the salient cytologic features of Grades 1-3 meningiomas.
  • It demonstrates that it is difficult to separate Grade 1 from Grade-2 meningioma on CP, and last, Grade-3 meningioma can be easily diagnosed on CP.
  • [MeSH-major] Cytological Techniques / methods. Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18831022.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Sughrue ME, Sanai N, Shangari G, Parsa AT, Berger MS, McDermott MW: Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. J Neurosurg; 2010 Aug;113(2):202-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas.
  • OBJECT: Despite an increased understanding of the biology of malignant meningioma tumor progression, there is a paucity of published clinical data on factors affecting outcomes following treatment for these lesions.
  • CONCLUSIONS: Surgery is an effective treatment for WHO Grade III meningiomas at presentation and recurrence; however, aggressive attempts to achieve gross-total resection can be associated with significant neurological risk.
  • [MeSH-major] Meningeal Neoplasms. Meningioma. Neoplasm Recurrence, Local. Reoperation / mortality

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2010 Aug;113(2):199-200; discussion 200-1 [20225919.001]
  • [CommentIn] J Neurosurg. 2015 Jun;122(6):1514-5 [25859809.001]
  • (PMID = 20225922.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


80. Jiang WH, Xiao JY, Zhao SP, Xie ZH, Zhang H: Resection of extensive sellar tumors with extended endoscopic transseptal transsphenoidal approach. Eur Arch Otorhinolaryngol; 2007 Nov;264(11):1301-8
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient with malignant meningioma died due to recurrence of the tumor 2 years postoperation.
  • Another one patient with malignant inverted papilloma recurred 1 year postoperation and underwent operation and radiation therapy again.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laryngol Otol. 1995 Oct;109(10):956-62 [7499948.001]
  • [Cites] Neurosurgery. 2002 Sep;51(3):699-705; discussion 705-7 [12188948.001]
  • [Cites] Minim Invasive Neurosurg. 2001 Mar;44(1):1-12 [11409304.001]
  • [Cites] Kurume Med J. 1998;45(1):53-7 [9658751.001]
  • [Cites] Arq Neuropsiquiatr. 2003 Sep;61(3B):836-41 [14595492.001]
  • [Cites] Neurosurgery. 2006 Jul;59(1 Suppl 1):ONS75-83; discussion ONS75-83 [16888556.001]
  • [Cites] Neurosurgery. 1997 Sep;41(3):602-7 [9310977.001]
  • [Cites] Surg Neurol. 2000 Feb;53(2):168-72; discussion 172-3 [10713196.001]
  • [Cites] Neurosurg Focus. 1996 Jul 15;1(1):e1; discussion 1p following e3 [15095996.001]
  • [Cites] J Neurosurg. 2000 Jun;92(6):1028-35 [10839266.001]
  • [Cites] Acta Neurochir (Wien). 1997;139(4):343-7; discussion 347-8 [9202775.001]
  • [Cites] Neurol Res. 2002 Apr;24(3):259-65 [11958419.001]
  • [Cites] J Laryngol Otol. 1994 Jan;108(1):19-22 [8133158.001]
  • [Cites] Otolaryngol Head Neck Surg. 2002 Nov;127(5):409-16 [12447234.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):225-36; discussion 236-7 [9007854.001]
  • [Cites] J Neurosurg. 1987 Jan;66(1):140-2 [3783248.001]
  • [Cites] Br J Neurosurg. 1994;8(2):193-6 [7917091.001]
  • [Cites] Am J Rhinol. 1998 Jul-Aug;12(4):283-7 [9740924.001]
  • [Cites] J Neurosurg. 1997 Jul;87(1):44-51 [9202264.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Dec;126(12):1487-90 [11115288.001]
  • [Cites] Laryngoscope. 1992 Feb;102(2):198-202 [1738293.001]
  • [Cites] Laryngoscope. 1996 Jul;106(7):914-8 [8667994.001]
  • [Cites] Clin Neurosurg. 1969;16:185-217 [5811707.001]
  • [Cites] Neurosurgery. 1997 May;40(5):944-6 [9149252.001]
  • [Cites] Surg Neurol. 1997 Mar;47(3):213-22; discussion 222-3 [9068690.001]
  • [Cites] Mayo Clin Proc. 1999 Jul;74(7):661-70 [10405694.001]
  • (PMID = 17549504.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


81. Moradi A, Semnani V, Djam H, Tajodini A, Zali AR, Ghaemi K, Nikzad N, Madani-Civi M: Pathodiagnostic parameters for meningioma grading. J Clin Neurosci; 2008 Dec;15(12):1370-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathodiagnostic parameters for meningioma grading.
  • Meningiomas are usually slow-growing benign tumors, for which complete removal can be difficult and recurrence is an issue.
  • In this study the relationship between pathodiagnostic parameters, histological grade, and MIB-1 monoclonal antibody expression in meningioma diagnosed over 10 years in Shohada Hospital, Tehran, was assessed.
  • Between January 1997 and December 2006, a total of 4885 intracranial tumors were diagnosed at Shohada Hospital, 378 (7.74%) of which were meningiomas.
  • All slides stained with hematoxylin and eosin were reviewed by two independent pathologists and all the diagnoses reconfirmed; histological anaplasia was classified according to the grading of the WHO Working Group 2000 as benign (Grade I), atypical with incipient signs of anaplasia (Grade II), or overtly anaplastic (Grade III).
  • The mean age of patients with meningiomas was 49.11+/-12.99 years (range 6-78 years, median=50); females outnumbered males by a ratio of 1.7 to 1.
  • Convexity meningiomas were most common, followed by meningiomas of the sphenoid ridge and cerebellopontine angle.
  • Histopathological study of completely resected meningiomas showed that loss of architecture, frequent mitotic figures, a high cellularity, increased nucleo-cytoplasmic ratio, a prominent nucleolus, brain invasion, and necrosis were correlated with the grade of the meningiomas.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18819804.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


82. Kalamarides M, Stemmer-Rachamimov AO, Takahashi M, Han ZY, Chareyre F, Niwa-Kawakita M, Black PM, Carroll RS, Giovannini M: Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. Brain Pathol; 2008 Jan;18(1):62-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.
  • Meningiomas account for approximately 30% of all primary central nervous system tumors and are found in half of neurofibromatosis type 2 patients often causing significant morbidity.
  • Although most meningiomas are benign, 10% are classified as atypical or anaplastic, displaying aggressive clinical behavior.
  • Biallelic inactivation of the neurofibromatosis 2 (NF2) tumor suppressor is associated with meningioma formation in all NF2 patients and 60% of sporadic meningiomas.
  • Deletion of the p16(INK4a)/p14(ARF) locus is found in both benign and malignant meningiomas, while mutation of the p53 tumor suppressor gene is uncommon.
  • Previously, we inactivated Nf2 in homozygous conditional knockout mice by adenoviral Cre delivery and showed that Nf2 loss in arachnoid cells is rate-limiting for meningioma formation.
  • Here, we report that additional nullizygosity for p16(Ink4a) increases the frequency of meningioma and meningothelial proliferation in these mice without modifying the tumor grade.
  • In addition, by using magnetic resonance imaging (MRI) to screen a large cohort of mutant mice, we were able to detect meningothelial proliferation and meningioma development opening the way to future studies in which therapeutic interventions can be tested as preclinical assessment of their potential clinical application.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / genetics. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology. Neurofibromin 2 / genetics

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 2005 Apr;15(2):109-15 [15912882.001]
  • [Cites] Mol Cell Biol. 2005 Mar;25(6):2384-94 [15743831.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3355-8, discussion 3358-9 [16585152.001]
  • [Cites] J Clin Invest. 2006 Apr;116(4):847-52 [16585951.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):504-12 [10850863.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2887 [10870076.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):197-201 [11266526.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] Nature. 2001 Sep 6;413(6851):83-6 [11544530.001]
  • [Cites] Cell. 2001 Sep 7;106(5):531-4 [11551500.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):149-58 [11859969.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1060-5 [12000789.001]
  • [Cites] Mol Cells. 2002 Aug 31;14(1):108-14 [12243339.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5551-8 [12359767.001]
  • [Cites] Neurosurgery. 2004 Jan;54(1):55-63; discussion 63-4 [14683541.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3718-24 [15150133.001]
  • [Cites] Oncogene. 2004 Aug 26;23(39):6541-7 [15221010.001]
  • [Cites] Radiology. 1986 Nov;161(2):369-75 [3763903.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Cell. 1996 Apr 5;85(1):27-37 [8620534.001]
  • [Cites] J Neurosci. 1997 Apr 1;17(7):2376-82 [9065498.001]
  • [Cites] Cell. 1997 Nov 28;91(5):649-59 [9393858.001]
  • [Cites] Genes Dev. 1998 Oct 1;12(19):2984-91 [9765200.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Ann Neurol. 2005 Jan;57(1):119-27 [15622533.001]
  • (PMID = 17924978.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Neurofibromin 2
  • [Other-IDs] NLM/ PMC2253711
  •  go-up   go-down


83. Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A, Rabkin SD: Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res; 2006 Nov 15;12(22):6791-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: A mouse Nf1:p53 malignant peripheral nerve sheath tumor (MPNST) cell line expressing dnFGFR was generated by transfection.
  • RESULTS: MPNST 61E4 cells expressing dnFGFR grew less well than parental control cells. bG47Delta-dnFGFR showed enhanced killing of both tumor (human U87 glioma and F5 malignant meningioma cells and murine MPNST 61E4 and 37-3-18-4 cells) and proliferating endothelial cells (human umbilical vascular endothelial cell and Py-4-1) in vitro compared with the control vector bG47Delta-empty without inhibiting viral replication.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17121900.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS032677
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Receptors, Fibroblast Growth Factor; 0 / Recombinant Proteins
  •  go-up   go-down


84. Balme E, Roth DR, Perentes E: Malignant spinal meningioma in a CD-1 mouse. Exp Toxicol Pathol; 2008 Aug;60(4-5):263-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant spinal meningioma in a CD-1 mouse.
  • Spontaneous meningiomas are extremely rare tumors in small laboratory animals, except in some strains of rats and in the B6C3F1 mouse.
  • Microscopic examination revealed the presence of a malignant meningioma (approximately 3mm in diameter) at the distal lumbar level of the spinal cord, invading the vertebral canal, and bilaterally the ventral and dorsal nerve roots and the dorsal root ganglia.
  • The diagnosis of malignant spinal meningioma was based on the morphologic features of the neoplasm, the evidence of local invasion and the immunohistochemical results.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / veterinary. Meningioma / pathology. Meningioma / veterinary. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / veterinary

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18485685.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Vimentin
  •  go-up   go-down


85. Li XZ, Zhao JZ: [Operation of lateral ventricular meningiomas of the trigone]. Zhonghua Yi Xue Za Zhi; 2006 Sep 5;86(33):2321-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Operation of lateral ventricular meningiomas of the trigone].
  • OBJECTIVE: To summarize the surgical treatment of intraventricular trigonal meningiomas.
  • METHOD: 64 cases of intraventricular trigonal meningiomas were retrospectively analyzed.
  • Pathological diagnosis included 35 fibrous, 10 mixed, 8 endothelial, 3 transitional, 1 secretion and 1 malignant meningioma.
  • CONCLUSION: Transcortical parieto-occipital approach and Transcortical temporo-parieto-occipital approaches are applicable for intraventricular trigonal meningiomas.
  • [MeSH-major] Lateral Ventricles / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17156626.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


86. Kano H, Takahashi JA, Katsuki T, Araki N, Oya N, Hiraoka M, Hashimoto N: Stereotactic radiosurgery for atypical and anaplastic meningiomas. J Neurooncol; 2007 Aug;84(1):41-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery for atypical and anaplastic meningiomas.
  • Atypical and anaplastic meningiomas frequently recur in the relatively short-term after surgery.
  • The objective of this report was assessment of the degree of tumor control, the risk of complications, and the presence of variables that predict outcome in patients treated with SRS for high-grade meningiomas.
  • We reviewed 12 high-grade meningioma patients with 30 lesions treated by Linac-based SRS at Kyoto University Hospital between 1997 and 2002.
  • They included 10 atypical meningiomas and 2 anaplastic ones according to the WHO classification.
  • The marginal dose <20 Gy was a statistically significant factor for a short-term progression in high-grade meningiomas (P = 0.0139).
  • In conclusion, based on our findings, we suggest that recurrent high-grade meningiomas be treated by SRS with a marginal dose exceeding 20 Gy.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Recurrence, Local / surgery. Radiosurgery / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17361335.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


87. Giussani C, Pirillo D, Roux FE: Mirror of the soul: a cortical stimulation study on recognition of facial emotions. J Neurosurg; 2010 Mar;112(3):520-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: After a preoperative neuropsychological evaluation, 18 consecutive patients with right hemispheric lesions (5 metastases, 6 high-grade gliomas, 4 low-grade gliomas, 2 arteriovenous malformations, and 1 malignant meningioma) were tested by intraoperative cortical stimulation while performing a facial emotion recognition task along with sensorimotor and visuospatial tasks.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538049.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Milker-Zabel S, Zabel-du Bois A, Ranai G, Trinh T, Unterberg A, Debus J, Lipson KE, Abdollahi A, Huber PE: SU11657 enhances radiosensitivity of human meningioma cells. Int J Radiat Oncol Biol Phys; 2008 Mar 15;70(4):1213-8
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SU11657 enhances radiosensitivity of human meningioma cells.
  • PURPOSE: To analyze the effect of the multireceptor tyrosine kinase inhibitor SU11657 (primarily vascular endothelial growth factor, platelet-derived growth factor) in combination with irradiation in freshly isolated primary human meningioma cells.
  • METHODS AND MATERIALS: Tumor specimens were obtained from meningioma patients undergoing surgery at the Department of Neurosurgery, University of Heidelberg, Germany.
  • Benign and atypical meningioma cells and human umbilical vein endothelial cells (HUVEC) were treated with SU11657 alone and in combination with 6-MV photons (0-10 Gy).
  • RESULTS: Radiation and SU11657 alone reduced cell proliferation in atypical and benign meningioma cells as well as in HUVEC in a dose-dependent manner.
  • SU11657 alone also reduced clonogenic survival of benign and atypical meningioma cells.
  • SU11657 increased radiosensitivity of human meningioma cells in clonogenic survival and cell number/proliferation assays.
  • The anticlonogenic and antiproliferative effects alone and the radiosensitization effects of SU11657 were more pronounced in atypical meningioma cells compared with benign meningioma cells.
  • CONCLUSION: Small-molecule tyrosine kinase inhibitors like SU11657 are capable of amplifying the growth inhibitory effects of irradiation in meningioma cells.
  • These data provide a rationale for further clinical evaluation of this combination concept, especially in atypical and malignant meningioma patients.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Organic Chemicals / pharmacology. Radiation Tolerance / drug effects. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18234428.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Organic Chemicals; 0 / SU 11657; 0 / Vascular Endothelial Growth Factors; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


89. Nakamura Y, Shimizu T, Ohigashi Y, Itou N, Ishikawa Y: Meningioma arising in Werner syndrome confirmed by mutation analysis. J Clin Neurosci; 2005 May;12(4):503-6
Genetic Alliance. consumer health - Werner's syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma arising in Werner syndrome confirmed by mutation analysis.
  • OBJECTIVE AND IMPORTANCE: Meningioma arising in Werner syndrome has been described previously, but never in association with a mutation analysis.
  • We present the first reported case of meningioma in a patient with Werner syndrome and a confirmed major mutation.
  • In addition, we review 27 previously reported patients with meningioma associated with Werner syndrome.
  • CLINICAL PRESENTATION: We report a 56-year-old Japanese woman with Werner syndrome and a meningioma.
  • Pathological examination after surgical removal confirmed meningioma.
  • INVESTIGATION: To confirm the clinical diagnosis, a mutation analysis based on the mutant allele-specific amplification (MASA) method was performed.
  • There were 22 patients with Werner syndrome and meningioma reported from Japan and 5 from outside Japan.
  • There was only one malignant meningioma.
  • Meningiomas in Werner syndrome have a higher frequency in males and occur at a younger age than those of the general population.
  • [MeSH-major] Meningeal Neoplasms / genetics. Meningioma / genetics. Mutation. Werner Syndrome / genetics

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925797.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


90. Ferchichi L, Bellil S, Ben Hammouda K, Bellil K, Mekni A, Bettaieb I, Haouet S, Khaldi MM, Zitouna K, Kchir N: Anaplastic secretory meningioma: a case report. Pathologica; 2006 Apr;98(2):153-5
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic secretory meningioma: a case report.
  • Secretory meningiomas are rare histological subtypes of meningiomas with benign biological behaviour.
  • In this study, the authors describe the first case of secretory meningioma with many mitotic figures and brain invasion, and discuss the clinicopathologic features including immunohistochemical staining profile and ultrastructural appearance of this tumour.
  • The histological diagnosis was secretory meningioma with many mitotic figures, a high MIB-1 labeling index and a brain invasion.
  • [MeSH-major] Frontal Lobe / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929789.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Ki-67 Antigen; 0 / Mucin-1; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


91. Toktas ZO, Akgun E, Ozkan A, Bozkurt SU, Bekiroglu N, Seker A, Konya D, Kilic T: Relationship of angiogenic potential with clinical features in cranial meningiomas: a corneal angiogenesis study. Neurosurgery; 2010 Dec;67(6):1724-32; discussion 1732

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of angiogenic potential with clinical features in cranial meningiomas: a corneal angiogenesis study.
  • BACKGROUND: Intracranial meningiomas constitute approximately one fourth of all primary intracranial tumors.
  • The invention of cranial angiographic techniques has led to the recognition of the angiogenic potential of meningiomas, which has been the subject of extensive research.
  • OBJECTIVE: To test the relationship between the angiogenetic potential of intracranial meningiomas and clinical/prognostic features such as World Health Organization (WHO) grade, peritumoral edema, tumor border shape, and recurrence using rat corneal angiogenesis assay.
  • METHODS: Fifteen WHO grade I (typical), 10 WHO grade II (atypical), and 5 WHO grade III (malignant) meningioma samples were implanted in the micropockets formed on rat corneas, and the number of developed vessels were counted on days 5, 10, 15, and 20.
  • CONCLUSION: Our findings, based on a dynamic in vivo model to examine angiogenesis, demonstrate that the angiogenic potential of meningiomas is correlated with WHO grade, recurrence, and possibly with tumor border shape and peritumoral edema.
  • Angiogenesis seems to be an important factor in the natural course of meningiomas, suggesting that inhibition of angiogenesis may be an option, particularly in the treatment of meningiomas with an aggressive course.
  • [MeSH-major] Corneal Neovascularization / etiology. Corneal Neovascularization / pathology. Meningeal Neoplasms / complications. Meningioma / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21107204.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


92. Zhou K, Wang G, Wang Y, Jin H, Yang S, Liu C: The potential involvement of E-cadherin and beta-catenins in meningioma. PLoS One; 2010;5(6):e11231
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potential involvement of E-cadherin and beta-catenins in meningioma.
  • OBJECTIVE: To investigate the potential involvements of E-cadherin and beta-catenin in meningioma.
  • METHODS: Immunohistochemistry staining was performed on samples from patients with meningioma.
  • The expression of E-cadherin and beta-catenin in meningioma was analyzed by its relationship with WHO2007 grading, invasion, peritumoral edema and postoperative recurrence.
  • RESULTS: The positive rates of E-cadherin in meningioma WHO I, II, III were 92.69%, 33.33% and 0, respectively, (P<0.05); while the positive rates of beta-catenin in meningioma WHO I, II, III were 82.93%, 33.33% and 20.00%, respectively, (P<0.05).
  • The positive rate of E-cadherin in meningioma without invasion (94.12%) was higher than that with invasion (46.67%) (P<0.05).
  • The difference in the positive rate of beta-catenin between meningioma without invasion (88.24%) and meningioma with invasion (33.33%, P<0.05) was also statically significant.
  • The positive rates of E-cadherin in meningioma with peritumoral edema 0, 1, 2, 3 were 93.75%, 85.71%, 60.00% and 0 respectively, (P<0.05); the positive rates of beta-catenin in meningioma with peritumoral edema 0, 1, 2, 3 were 87.50%, 85.71%, 30.00% and 0 respectively, (P<0.01).
  • The positive rates of E- cadherin in meningioma with postoperative recurrence were 33.33%, and the positive rate with postoperative non-recurrence was 90.00% (P<0.01).
  • The positive rates of beta-catenin in meningioma with postoperative recurrence and non-recurrence were 11.11%, 85.00%, respectively (P<0.01).
  • CONCLUSION: The expression levels of E- cadherin and beta-catenin correlated closely to the WHO 2007 grading criteria for meningioma.
  • In atypical or malignant meningioma, the expression levels of E-cadherin and beta-catenin were significantly lower.
  • The expression levels of E- cadherin and beta-catenin were also closely correlated with the invasion status of meningioma, the size of the peritumoral edema and the recurrent probabilities of the meningioma, all in an inverse correlationship.
  • Taken together, the present study provided novel molecular targets in clinical treatments to meningioma.
  • [MeSH-major] Cadherins / metabolism. Meningioma / metabolism. beta Catenin / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):996-1001 [15986431.001]
  • [Cites] Clin Neuropathol. 2005 Jan-Feb;24(1):8-12 [15696778.001]
  • [Cites] Histopathology. 2006 Aug;49(2):178-87 [16879395.001]
  • [Cites] Rev Med Chil. 2006 Aug;134(8):1002-9 [17130988.001]
  • [Cites] Anticancer Res. 2007 Sep-Oct;27(5A):3083-9 [17970048.001]
  • [Cites] Int Urol Nephrol. 2007;39(4):1031-7 [17340210.001]
  • [Cites] Cell Tissue Res. 2008 Feb;331(2):401-12 [17965884.001]
  • [Cites] Biochem Soc Trans. 2008 Apr;36(Pt 2):141-7 [18363554.001]
  • [Cites] Genet Mol Res. 2008;7(2):295-304 [18551395.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Aug;67(2):153-71 [18342535.001]
  • [Cites] Mol Biosyst. 2008 Aug;4(8):835-50 [18633485.001]
  • [Cites] Trends Neurosci. 2008 Sep;31(9):487-94 [18684518.001]
  • [Cites] Virchows Arch. 2008 Sep;453(3):267-74 [18712413.001]
  • [Cites] Clin Neuropathol. 2008 Sep-Oct;27(5):334-45 [18808065.001]
  • [Cites] Surg Neurol. 2008 Nov;70(5):471-7; discussion 477 [18586307.001]
  • [Cites] Cell Commun Adhes. 2008 Nov;15(4):365-78 [18937087.001]
  • [Cites] Eur J Gynaecol Oncol. 2008;29(5):489-92 [19051819.001]
  • [Cites] Cell Mol Life Sci. 2008 Nov;65(23):3756-88 [18726070.001]
  • [Cites] Genomics. 1995 Mar 20;26(2):281-9 [7601454.001]
  • [Cites] Neurosurgery. 1997 Jun;40(6):1269-77 [9179901.001]
  • [Cites] J Neurooncol. 2004 Oct;70(1):3-15 [15527101.001]
  • [Cites] Pathol Int. 2005 Jan;55(1):1-7 [15660696.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7951-7 [16258095.001]
  • (PMID = 20574529.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / beta Catenin
  • [Other-IDs] NLM/ PMC2888586
  •  go-up   go-down


93. Lah TT, Nanni I, Trinkaus M, Metellus P, Dussert C, De Ridder L, Rajcević U, Blejec A, Martin PM: Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. J Neurosurg; 2010 May;112(5):940-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors.
  • OBJECT: The first aim of this study was to diagnose more aggressive and potentially recurrent meningiomas using an in vitro embryonic chick heart invasiveness assay in which lysosomal enzyme cathepsin B was used as the invasiveness marker.
  • The second aim was to confirm if cathepsin B and/or cathepsin L and their endogenous inhibitors were also prognostic parameters in the clinical study of 119 patients with meningioma.
  • METHODS: Primary meningioma cultured spheroids were "confronted" with embryonic chick heart spheroids in vitro, and cathepsin B was used as molecular marker to immunolabel the invasive tumor cells.
  • In vitro invasion assays of the malignant meningioma cells were used to assess the invasive potential related to the cysteine cathepsins.
  • As to the second aim, the possible association of cathepsin B along with selected molecular markers, cathepsin L, and endogenous cysteine protease inhibitors (stefins A and B and cystatin C) with meningioma malignancy was determined using enzyme-linked immunosorbent assays in tumor homogenates.
  • Univariate and multivariate analyses were used to compare these parameters with established biological markers of meningioma recurrence in 119 patients with meningiomas.
  • RESULTS: The more invasive tumors, which characteristically overgrew the normal tissue, were identified even within a group of histologically benign meningiomas.
  • Matrigel invasion of malignant meningioma cells was significantly altered by modulating cathepsin B activity and by stefin B silencing.
  • In the clinical samples of meningioma, the levels of cathepsins B and L, stefin B, and cystatin C were highest in the tumors of higher histological grades, whereas stefin A and progesterone receptor were the only markers that were significantly increased and decreased, respectively, in WHO Grade III lesions.
  • CONCLUSIONS: The data indicate that the cysteine cathepsins and their inhibitors are involved in a process related to early meningioma recurrence, regardless of their histological classification.
  • Of note, the known tumor invasiveness marker cathepsin B, measured in whole-tumor homogenates, was not prognostic, in contrast to its endogenous inhibitor stefin B, which was highly significant and the only independent prognostic factor to predict meningioma relapse in multivariate analysis and reported herein for the first time.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Cysteine Proteinase Inhibitors / pharmacology. Cysteine Proteinase Inhibitors / therapeutic use. Lysosomes / drug effects. Meningioma / drug therapy. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19747051.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CSTB protein, human; 0 / Cystatin A; 0 / Cysteine Proteinase Inhibitors; 88844-95-5 / Cystatin B; EC 3.4.22.1 / CTSB protein, human; EC 3.4.22.1 / Cathepsin B
  •  go-up   go-down


94. Gogineni VR, Kargiotis O, Klopfenstein JD, Gujrati M, Dinh DH, Rao JS: RNAi-mediated downregulation of radiation-induced MMP-9 leads to apoptosis via activation of ERK and Akt in IOMM-Lee cells. Int J Oncol; 2009 Jan;34(1):209-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients afflicted with meningiomas are most often treated with radiation therapy followed by surgical resection.
  • In this study, we demonstrate that the malignant meningioma cells (IOMM-Lee cells) overexpress MMP-9 at both the mRNA and protein levels after radiation treatment.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2006 Nov 9;25(53):7009-18 [16732316.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8511-9 [16951163.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):789-801 [17363476.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4956-64 [17510426.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1171-80 [17634416.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2307-16 [17657740.001]
  • [Cites] Surg Neurol. 2007 Dec;68(6):610-3; discussion 613-4 [17765959.001]
  • [Cites] J Biol Chem. 2008 Jan 18;283(3):1545-52 [17991734.001]
  • [Cites] Int J Oncol. 2008 Mar;32(3):557-64 [18292932.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1161-9 [12829155.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5967-75 [12955075.001]
  • [Cites] Cancer Gene Ther. 2003 Nov;10(11):823-32 [14605668.001]
  • [Cites] Biol Chem. 2004 Jan;385(1):75-86 [14977049.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):147-57 [15072462.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2B):967-72 [15161051.001]
  • [Cites] Neurotoxicology. 2004 Dec;25(6):915-24 [15474610.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61 [10656373.001]
  • [Cites] Ann Surg. 2000 May;231(5):644-54 [10767785.001]
  • [Cites] J Neurooncol. 2000 May;48(1):51-5 [11026697.001]
  • [Cites] Int J Cancer. 2000 Dec 1;88(5):766-71 [11072246.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):151-60 [11083080.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2744-50 [11289157.001]
  • [Cites] J Neurosurg. 2001 Jun;94(6):978-84 [11409528.001]
  • [Cites] Adv Exp Med Biol. 2000;486:355-9 [11783515.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4932-44 [11733515.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1223-7 [11948136.001]
  • [Cites] Biochem J. 2002 Jul 1;365(Pt 1):31-40 [12071839.001]
  • [Cites] Oncogene. 2002 Aug 15;21(36):5601-8 [12165859.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Neurosurgery. 1987 Apr;20(4):525-8 [3587542.001]
  • [Cites] BMC Cancer. 2002 Dec 3;2:34 [12464160.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] Med Phys. 1995 Nov;22(11 Pt 2):1889-97 [8587542.001]
  • [Cites] Pflugers Arch. 1998 Mar;435(4):546-54 [9446703.001]
  • [Cites] J Surg Res. 1999 Jun 15;84(2):162-7 [10357914.001]
  • [Cites] J Appl Toxicol. 2005 Sep-Oct;25(5):374-82 [16013042.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):99-103 [16193379.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):6785-93 [16709838.001]
  • [Cites] J Neurooncol. 2006 Mar;77(1):73-7 [16292489.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Dec;319(3):991-7 [16801453.001]
  • (PMID = 19082492.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS061835; United States / NINDS NIH HHS / NS / R01 NS057529; United States / NCI NIH HHS / CA / R01 CA075557; United States / NCI NIH HHS / CA / R01 CA116708-03; United States / NCI NIH HHS / CA / R01 CA095058-04; United States / NINDS NIH HHS / NS / R01 NS057529-02; United States / NINDS NIH HHS / NS / R01 NS061835-01; United States / NCI NIH HHS / CA / CA 75557; United States / NCI NIH HHS / CA / CA116708-03; United States / NCI NIH HHS / CA / CA075557-10; United States / NCI NIH HHS / CA / CA 92393; United States / NINDS NIH HHS / NS / NS061835-01; United States / NCI NIH HHS / CA / CA 95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NINDS NIH HHS / NS / NS057529-02; United States / NCI NIH HHS / CA / CA092393-04; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA 116708; United States / NCI NIH HHS / CA / R01 CA092393-04; United States / NINDS NIH HHS / NS / R01 NS047699-04A2; United States / NINDS NIH HHS / NS / NS047699-04A2; United States / NCI NIH HHS / CA / CA095058-04; United States / NCI NIH HHS / CA / R01 CA075557-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Drug Combinations; 0 / Enzyme Inhibitors; 0 / FAS protein, human; 0 / Laminin; 0 / Matrix Metalloproteinase Inhibitors; 0 / Proteoglycans; 0 / RNA, Small Interfering; 119978-18-6 / matrigel; 9007-34-5 / Collagen; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ NIHMS71812; NLM/ PMC2605673
  •  go-up   go-down


95. Girish V, Sachdeva N, Minz RW, Radotra B, Mathuria SN, Arora SK: Bcl2 and ROS1 expression in human meningiomas: an analysis with respect to histological subtype. Indian J Pathol Microbiol; 2005 Jul;48(3):325-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl2 and ROS1 expression in human meningiomas: an analysis with respect to histological subtype.
  • Among oncogenes, bcl2, an anti-apoptotic factor and ROS1 that encodes a protein with a structure similar to the epidermal growth factor (EGF) and insulin receptor and has a tyrosine kinase activity, have been shown to be associated with many malignant tumors.
  • In the present study we have analysed the expression of bcl2 using immuno-histochemistry and ROS1 expression by reverse-transcription coupled with polymerase chain reaction (RT-PCR) of the transcript using primers specific for the intra-cellular domain and then tried to correlate the findings with the subtype of the meningioma defined on the basis of histology.
  • Out of the six bcl2 positive cases in our study, there were three transitional tumors, two fibroblastic and one recurrent meningioma subtype. bcl2 seemed to be more consistently expressed in the cytoplasm of spindle cell component of meningiomas.
  • Thirteen meningiothelial meningiomas did not show any staining for bcl2.
  • ROS1 gene expression could be detected in 4 tumors all of those were Grade-I meningothelial meningiomas.
  • One of the malignant meningioma included in the study was clearly negative for bcl2 as well as ROS1.
  • Thus bcl2 and ROS1 oncogene expression in meningiomas are not concurrent and neither can be ascribed to any histologic subtype or grade of tumor.
  • [MeSH-major] Genes, bcl-2. Meningeal Neoplasms / pathology. Meningioma / pathology. Protein-Tyrosine Kinases / metabolism. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16761743.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / ROS1 protein, human
  •  go-up   go-down


96. Chen YY, Tiang XY, Li Z, Luo BN, Huang Q: Sporadic meningioangiomatosis-associated atypical meningioma mimicking parenchymal invasion of brain: a case report and review of the literature. Diagn Pathol; 2010;5:39
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic meningioangiomatosis-associated atypical meningioma mimicking parenchymal invasion of brain: a case report and review of the literature.
  • In extremely rare condition, meningioma may occur together with meningioangiomatosis, and only 19 cases have been described in English literature until now.
  • We now report a case of meningioangiomatosis-associated meningioma with atypical and clear cell variant.
  • Microscopically, parts of lesions were atypical and clear cell meningioma corresponding to WHO grade II.
  • Neoplastic cells in atypical meningioma area were immunoreactive to epithelial membrane antigen (EMA) with high MIB-1 index of up to 20%.
  • The diagnosis of atypical meningioma associated with sporadic meningioangiomatosis was made.
  • To our knowledge, this is the first case of a meningioangiomatosis-associated meningioma with atypical and clear cell variant component to be described.
  • Meningioangiomatosis-associated meningioma is more likely to occur in younger patients and histologically to mimic parenchymal invasion of brain.
  • We suggest that postoperative radiotherapy or chemotherapy should be given careful consideration to avoid over-treatment due to erroneously interpret as malignant meningioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Central Nervous System Vascular Malformations / diagnosis. Cerebral Cortex / pathology. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2000 Apr;92(4):706-10 [10761664.001]
  • [Cites] Acta Cytol. 2009 Jan-Feb;53(1):93-7 [19248561.001]
  • [Cites] Pediatr Dev Pathol. 2001 Nov-Dec;4(6):568-72 [11826364.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Feb;28(1):48-56 [11849563.001]
  • [Cites] Nervenarzt. 2002 Oct;73(10):990-4 [12376888.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Apr;29(2):170-4 [12662324.001]
  • [Cites] Brain Pathol. 2003 Oct;13(4):643-5 [14655769.001]
  • [Cites] Am J Clin Pathol. 1974 Oct;62(4):481-7 [4212953.001]
  • [Cites] J Neurosurg. 1982 Jan;56(1):154-7 [7054414.001]
  • [Cites] Acta Neuropathol. 1987;73(4):361-4 [3618128.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):715-9 [2213161.001]
  • [Cites] Pathol Res Pract. 1992 Feb;188(1-2):145-7 [1594484.001]
  • [Cites] J Neurosurg. 1993 Feb;78(2):287-9 [8421212.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):485-9 [9143261.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):872-5 [10435554.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):55-65 [15779237.001]
  • [Cites] Childs Nerv Syst. 2006 Jan;22(1):78-83 [16389566.001]
  • [Cites] Surg Neurol. 2006 Jun;65(6):595-603 [16720184.001]
  • [Cites] Am J Surg Pathol. 2002 Jan;26(1):125-9 [11756780.001]
  • (PMID = 20565869.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2904739
  •  go-up   go-down


97. Kim EY, Weon YC, Kim ST, Kim HJ, Byun HS, Lee JI, Kim JH: Rhabdoid meningioma: clinical features and MR imaging findings in 15 patients. AJNR Am J Neuroradiol; 2007 Sep;28(8):1462-5
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdoid meningioma: clinical features and MR imaging findings in 15 patients.
  • BACKGROUND AND PURPOSE: Rhabdoid meningioma (RM) is a recently described variant of malignant meningioma, with radiologic features currently not well characterized in the medical literature.
  • [MeSH-major] Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / physiopathology. Meningioma / diagnosis. Meningioma / physiopathology
  • [MeSH-minor] Adult. Aged. Cysts / diagnosis. Edema / chemically induced. Edema / etiology. Female. Follow-Up Studies. Humans. Hyperostosis / diagnosis. Hyperostosis / etiology. Male. Middle Aged. Neurosurgical Procedures. Radiotherapy, Adjuvant. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846191.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Nakasu S, Fukami T, Jito J, Matsuda M: Microscopic anatomy of the brain-meningioma interface. Brain Tumor Pathol; 2005;22(2):53-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microscopic anatomy of the brain-meningioma interface.
  • We analyzed the relation between meningioma and the brain in 50 surgical cases.
  • So-called capsule formation was seen in 20 meningiomas, of which 13 were categorized as thin and 7 as thick.
  • In 21 meningiomas the arachnoid membrane was intact, and 10 meningiomas had no underlying arachnoid membrane.
  • Meningiomas were usually demarcated by a basement membrane that was collagen type 4 (Col4)-positive.
  • However, atypical and anaplastic meningiomas usually lacked Col4 staining at the interface.
  • In two benign meningiomas that looked like an invasive growth, Col4 staining was seen above the brain.
  • [MeSH-major] Brain / ultrastructure. Meningeal Neoplasms / ultrastructure. Meningioma / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095106.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Amyloid beta-Protein Precursor; 0 / Collagen Type IV; 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / Neoplasm Proteins; 0 / Neurofilament Proteins; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


99. Paramanathan N, Ooi KG, Reeves D, Wilcsek GA: Synchronous radiation-induced orbital meningioma and multiple cavernomas. Clin Exp Ophthalmol; 2010 May;38(4):414-7
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous radiation-induced orbital meningioma and multiple cavernomas.
  • We present the first reported case of synchronous radiation-induced orbital meningioma and cavernomas of the cerebellum and bilateral basal ganglia, presenting 16 years after ionizing radiation therapy for parietal anaplastic ependymoma, at the age of five.
  • [MeSH-major] Basal Ganglia Diseases / etiology. Cerebellar Neoplasms / etiology. Hemangioma, Cavernous / etiology. Meningioma / etiology. Neoplasms, Multiple Primary / etiology. Neoplasms, Radiation-Induced. Orbital Neoplasms / etiology

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Radiation induced meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20491803.001).
  • [ISSN] 1442-9071
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


100. Goh KY, Poon WS, Chan DT, Ip CP: Tissue plasminogen activator expression in meningiomas and glioblastomas. Clin Neurol Neurosurg; 2005 Jun;107(4):296-300
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue plasminogen activator expression in meningiomas and glioblastomas.
  • OBJECTIVES: Enzyme-linked immunosorbent assay (ELISA) and Western blotting techniques were used to investigate and compare the expression of tissue plasminogen activator (tPA) in benign (meningioma) and malignant (glioblastoma) human brain tumours.
  • METHODS: A total of 22 tumour samples comprising 11 meningiomas and 11 glioblastomas with adjacent peritumoural tissue were analysed.
  • RESULTS: The mean tPA content of meningiomas was approximately half that of glioblastomas (55.40 (S.D.
  • Comparing tPA quantity in tumour and peritumoural tissue, there was a significant difference for meningiomas (55.40 (S.D.
  • Comparing tumour with normal brain tissue, there was no difference for meningiomas (55.40 (S.D.
  • Western blotting showed that in the meningioma group, the molecular weight pattern was constant with a dominant well-defined band at 41kD.
  • CONCLUSION: These results indicate that (1) tPA is present in larger quantities in glioblastoma compared to meningioma and normal brain, (2) tPA quantity is not significantly different in the peritumoural tissue adjacent to glioblastoma but is significantly less for meningioma, and (3) tPA is expressed in more heterogenous forms in glioblastoma.
  • This present study therefore suggests that the expression of tPA in a brain tumour may be an additional prognostic factor in terms of its malignant and invasive potential.
  • [MeSH-major] Brain Neoplasms / enzymology. Glioblastoma / enzymology. Meningeal Neoplasms / enzymology. Meningioma / enzymology. Tissue Plasminogen Activator / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15885387.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.21.68 / Tissue Plasminogen Activator
  •  go-up   go-down






Advertisement